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This study was undertaken to evaluate the safety and efficacy of Iodine-125 brachytherapy
(IBT) as a primary treatment for large uveal melanomas. Until recently, enucleation has been
the treatment of choice for large uveal melanomas in most centers. The Helsinki University
Eye Hospital, a national tertiary referral center managing more than 90% of uveal melanomas
in Finland, has since 1990 offered iodine brachytherapy for all patients unwilling to undergo
enucleation for a large uveal melanoma.
The first aim of the study was to assess survival, local tumor recurrence and
preservation of the eye and vision. The definition of a large tumor and most of the inclusion
criteria were adopted from the Collaborate Ocular Melanoma Study  (COMS) to facilitate
comparison of results with this large, prospective multi-center study in which only
enucleation was considered for large tumors. The second part of the study focused on the
complications of IBT and their risk factors, and the third part used computer models to assess
radiation dose delivered to key ocular structures during the treatment and the role of radiation
in the development of complications and vision loss. A collimating plaque design to reduce
radiation dose to healthy tissues was developed and tested using computer models. The last
part of the study compared transscleral local resection (TSR) with IBT in managing the
thickest large uveal melanomas, which were associated with a high risk of ocular morbidity
and vision loss after IBT in the first parts of the study.
I. Kaplan-Meier estimates of all-cause and melanoma-specific survival were 62%
and 65%, respectively, and visually comparable with the survival experience of patients
reported by the COMS. Local recurrence developed in 6% of eyes and 84% of eyes were
conserved at five years. Visual prognosis was guarded with 11% avoiding loss of 20/70 vision
and 26% avoiding loss of 20/400 vision in the tumor eye at two years. Large tumor height and
short distance from the posterior pole were independently associated with loss of vision.
II. Using cumulative incidence analysis to account for competing risks, such as
enucleation and metastatic death, the 5-year incidence of cataract was 79%, glaucoma 60%,
optic neuropathy 46%, maculopathy 52%, persistent or recurring retinal detachment (RD)
25%, and vitreous hemorrhage 36%. More than 80% of complications appeared within 3 years
of treatment. In multivariate competing risks regression models, increasing tumor height was
associated with cataract, iris neovascularization and RD. Maculopathy and optic neuropathy
were associated with distance from the tumor to the respective structure.
III. Dose to the optic disc was independently associated with optic neuropathy and
loss of vision. Optic neuropathy was rare with doses under 50 Gy. Both dose to the optic disc
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and dose to the macula predicted vision loss after IBT. Simulated treatment using collimating
plaques resulted in clinically meaningful reduction in both optic disc (median reduction, 30
Gy) and macular (median reduction, 36 Gy) doses as compared to the actual treatment.
IV. Patients managed with IBT for a uveal melanoma that was classified as large
according to the COMS criteria because of tumor height were compared with patients with
similarly-sized tumors managed with TSR in Liverpool, United Kingdom. Cumulative
incidence analysis and logistic regression models revealed that while long-term preservation
of 20/70 vision was rare in both treatment arms, preservation of 20/400 vision was better after
TSR (32% vs. 5% at 5 years). However, local tumor recurrence was also more common after
TSR than it was after IBT (Cumulative incidence 41% vs. 7% at five years, respectively).
In terms of survival, IBT seems to be a safe alternative to enucleation in managing
large uveal melanomas. Local tumor control is no worse than with medium-sized tumors and
the chances of avoiding secondary enucleation are good. Unfortunately, side-effects from
radiotherapy with the current brachytherapy protocol are frequent, and long-term prognosis of
saving reading and even ambulatory vision is consequently guarded. Because the means to
manage radiation damage to the optic nerve and macula are ineffective, decreasing the dose
absorbed by these critical structures should be one priority in brachytherapy planning. Even
when the risk for optic neuropathy and radiation maculopathy can be decreased by improved
plaques and treatment planning, persistent exudative retinal detachment, iris
neovascularization and neovascular glaucoma can still cause considerable ocular morbidity
and permanent loss of vision because of a large retained tumor mass after IBT.
At diagnosis patients with a large uveal melanoma can be informed of all available
treatment options and the benefits and risks associated with each one. In a setting with
frequent competing risks, such as early metastatic death, cumulative incidence analysis
provides more realistic estimates than the Kaplan-Meier method for patient counseling. If a
patient is unwilling to accept the risk of local recurrence and complications associated with
IBT and TSR, enucleation can be recommended as an effective and proven treatment. On the
other hand, if the patient places priority on saving vision, TSR with adjuvant ruthenium
brachytherapy can be considered as an alternative to IBT for tumors that are classified large
because of their height, provided the patient is fit to undergo hypotensive anesthesia and
willing to accept the substantial risk of local tumor recurrence. For other types of large uveal
melanoma, IBT remains an option that is safe and effective in controlling the tumor. Attention





Uveal melanoma, although a rare disease, is the most common primary intraocular
malignancy in adults. It is characterized by early and predominantly hematogenous
dissemination outside the eye and poor prognosis if clinical metastases develop. Vision in the
affected eye is threatened by both the tumor and side-effects from the treatments currently
available.
Uveal melanoma develops from melanocytes of the uveal tract which consists of
three anatomically distinct parts. The choroid, which is a layer of highly vascular tissue
between the light-sensitive retina and hard scleral shell, the ciliary body in the anterior
segment of the eye, and the iris.
Most uveal melanomas grow relatively slowly over years with no or few initial
symptoms, unless the tumor is very close to the foveal area of central visual acuity. Some are
detected by chance during routine eye examinations, and approximately one third reach a size
categorized as large before diagnosis. Delay in diagnosis is unfortunate, because tumor size is
a strong prognostic factor for both survival and conservation of vision: larger tumors are
associated with a higher risk of spawning metastases and are also more likely to develop
vision-threatening complications after current eye-conserving treatments.
Before the 1970s nearly all uveal melanomas were managed with enucleation. The
first experimental forms of radiotherapy emerged in the 1930s and the past three decades have
seen the development of several eye-conserving treatments based on both irradiation and
microsurgery. Currently, the vast majority of eyes with small to medium-sized melanomas
can be saved with these techniques, many with usable visual acuity. A growing body of
evidence suggests no survival benefit is gained or lost with effective eye-conserving treatment
compared to enucleation.
Large uveal melanomas carry a less favorable visual prognosis, and enucleation has
remained the treatment of choice in most centers. Yet, when reasonable hope for saving
usable vision exists or the patient refuses enucleation, several eye-conserving treatments can
be considered. These include charged particle therapy, fractionated stereotactic radiotherapy,
gamma knife radiosurgery, and plaque radiotherapy. Local resection is feasible for selected
large uveal melanomas. However, with a plethora of frequent and different side-effects
associated with each treatment, deciding which would best serve each patient can be a
perplexing task for the ocular oncologist.
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This study was undertaken to evaluate the safety and functional outcome of
episcleral iodine plaque brachytherapy, the most common and widely available eye-
conserving treatment for large uveal melanomas. A further aim was to identify the risk factors
for side-effects and consequent loss of vision in order to find means to improve the functional
prognosis for these patients. The first three parts of the study examine a population-based,
consecutive series of patients managed with iodine brachytherapy (IBT) in a national ocular
oncology center. In the fourth part, the results of IBT for a selected subgroup of these patients
are compared against transscleral local resection given in another tertiary referral center for
patients with similar tumors.
Review of Literature
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3. Review of Literature
3.1. Overview of Uveal Melanoma
3.1.1. Epidemiology
Uveal melanoma is the most common intraocular malignancy and the second most common
melanocytic tumor in humans. The reported annual age-standardized incidence has varied
from 4 to 11 per million in predominantly Caucasian populations.32;222;274;287 In Finland
(population, 5.2 million), the most recent estimate from the years 1955 to 1994 varies from
7.5 to 11 per million in males and 6.9 to 8.8 per million in females.286 In Sweden, between
1960 and 1998, the incidence was between 8.4 and 11.7 in males and between 10.3 and 8.7 in
females.32 The incidences in both Nordic countries are higher than the 4.3 per million recently
reported for the United States.274 Male predominance has been observed in several
studies,32;222;274;287 but the reason for this remains unknown. Uveal melanoma is rare among
non-Caucasians. It is estimated to be 150 times more common in Caucasian populations than
in Africans and those of Oriental ethnicity.80;182;274
Median age at diagnosis of uveal melanoma ranges from 55 to 65,67;80;189;222;252;274
and the disease is rare in children and teenagers.32;273 After the age of 20 the incidence rises
steadily from 0.5 per million, with steeper incline after the age of 40, to its peak at around 20
per million in the 60 to 70 years age group, after which it reaches a plateau.164;274 The
incidence of uveal melanoma has remained more or less stable over the years,32;274 in contrast
with the rising incidences of cutaneous melanoma,84 and conjunctival melanoma.298
Uveal melanoma is nearly always a unilateral disease. Less than 2 uveal melanoma
patients in 1000 have bilateral disease, i.e. a primary tumor in both eyes.272 This frequency is
higher than what would occur by chance, and a higher frequency of ocular melanocytosis has
been noted in the patients with bilateral disease.
3.1.2. Pathogenesis
3.1.2.1. Etiology and Predisposition
Uveal melanoma arises from melanocytes of the choroid, the ciliary body and the iris (Fig.1).
These cells are of neuroectodermal origin and similar to melanocytes found in the skin and the
conjunctiva. However, the uveal tumors have unique characteristics not shared with
melanomas occurring in other tissues. The structure of the eye, most notably the lack of
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lymphatic vessels, limit the growth and
dissemination of the tumor cells, resulting in
characteristic growth patterns and
predominantly hematogeneous dissemi-
nation.
It is estimated that, based on con-
secutive series, 64-90% of uveal melanomas
originate in the choroid,67;164;169;222 which is
a highly vascular layer of tissue located
between the retina and the sclera. The tumor
involves the ciliary body in 24-36% of
cases,164 but no more than 10% are thought
to initiate there.169;222 A study which
analyzed tumor initiation patterns in detail found it to have a predilection for the posterior
pole in all quadrants.169 Approximately 5% of tumors of choroidal or ciliary body origin
extend to the iris.169;222 Tumors initiating in the iris itself (iris melanomas) account for
approximately 3% of the melanomas of the uveal tract.145;222 These tumors differ sufficiently
from ciliochoroidal tumors in terms of treatment and prognosis to be considered a separate
entity.
The etiology of uveal melanoma is not known, although several potential risk factors
have been studied. In addition to race and age, lightly pigmented skin and light iris color have
been established as risk factors.135;240 The role of sunlight and other ultraviolet light exposure
has been documented in the etiology of cutaneous melanoma, but its association with uveal
melanoma is ambiguous.135;213;240;271 The risks associated with occupation, tobacco and
hormonal factors have also been studied but no conclusive evidence has been found.80;134;135
Congenital ocular and oculodermal melanocytosis (nevus of Ota) is a rare
pigmentary anomaly in which the number of melanocytes is increased in ocular and periocular
tissues. This disorder has been associated with an increased risk for uveal melanoma.106
Some uveal melanomas initiate from pre-existing choroidal nevi. In a population-
based study approximately one tumor in ten developed from a previously identified nevus.86
A nevus is a relatively common finding, with a prevalence of 3-20% in a normal
population.269;318 It has been estimated that roughly 1 choroidal nevus in 9000 undergo
malignant transformation into a melanoma per year.269;318
Figure 1. Diagram of the eye showing melanomas




Uveal melanoma is generally not considered hereditary, although some families with
increased incidence have been described.138;275 No gene responsible for the disease has been
found, but studies have identified several non-random abnormalities in the genome of many
uveal melanomas. The most consistent so far is the partial or total loss of chromosome 3,
sometimes referred to as monosomy 3.136 This genotype has been shown to correlate with
tumor size and aggressive behavior.218;236 Indeed, it has been suggested that uveal melanoma
cells with two fully functional chromosome 3s may not develop metastasis at all. Other
common chromosomal anomalies concern chromosomes 8 and 6.  Extra copies or gains in
chromosome 8 occur frequently together with monosomy 3 and carry an unfavorable
prognosis, whereas changes in chromosome 6 are inversely related with monosomy 3 and
associated with better prognosis.268 Although it is as yet unclear whether these changes lie on
the primary pathway of malignant transformation or are markers of tumor progression, their
discovery is an important breakthrough opening new avenues for prognostication and further
research.
3.1.2.3. Growth Patterns
Different growth patterns have been described for ciliochoroidal melanomas. When small,
most uveal melanomas are flat, hardly distinguishable from benign nevi.247;291 With time,
most tumors grow along the choroid as well as in thickness resulting in a solid nodular or
dome-shaped mass.145 A diffuse variant which may involve large areas of the choroid with
little increase in tumor thickness has been encountered in 3-5% of cases of posterior uveal
melanoma.96;255;293 Uveal melanoma is a slow-growing tumor. It has been estimated, based on
inferred natural history of uveal melanoma, that it takes an average of 7 years for a medium-
sized uveal melanoma of less than 10 mm in largest diameter to reach the large size of 15 mm
in diameter.19;187
A uveal melanoma eventually invades neighboring tissues. As a choroidal tumor
grows in height, it pushes against, weakens, and eventually ruptures through the Bruch’s
membrane. This herniation into the subretinal space results in the pathognomic mushroom or
collar-button shape and enables the tumor to grow in height more rapidly.146 In histological
examination of eyes enucleated because of uveal melanoma, ruptured Bruch’s membrane was
seen in 40-87%,145;222;293 and limited invasion of the overlying retina was documented in 26-
60%.145;293 Rarely, melanomas classified as retinoinvasive invade within the retina, cause
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intravitreal seeding and infiltration of the optic nerve.160 This type of growth occurs more
frequently in eyes with pre-existing or secondary glaucoma.
The lack of Bruch’s membrane in the ciliary body causes melanomas arising there to
follow a different growth pattern. The main tumor mass is often more hemispherical and can
grow to compress the iris and the lens, causing secondary angle closure and cataract. A
subclass of diffuse melanoma, the ring melanoma, grows circumferentially along the ciliary
body making it difficult to diagnose.74;166 The tumor can also invade the iris, the chamber
angle and trabecular meshwork.
Uveal melanomas also grow outward, invading the overlying sclera, usually by
growing along the vortex veins or emissary channels of the ciliary vessels and nerves.
Microscopic invasion of the inner sclera is common, occurring in 50% to 80% of enucleated
eyes.145;293 In the Collaborative Ocular Melanoma Study (COMS) series of enucleated
medium to large-sized tumors, tumor size was statistically associated with local invasion, with
large tumors more likely to invade the retina, the vitreous and the vortex veins. Invasion of
the emissary channels which occurred in approximately 56% of cases, was not related to
tumor size.293
Macroscopic extrascleral extension, the invasion of the orbit and or conjunctiva by
the tumor, has been reported in 2-17% cases of uveal melanoma.67;145;164;245;289 Extrascleral
growth has been associated with poorer prognosis,164;208 either through direct spread along the
orbital tissues and vasculature, or indirectly, as a sign of more aggressive tumor cells.
An uncommon site of intraocular invasion is the optic nerve. Invasion of the optic
nerve head is reported in 2-7% of eyes with uveal melanoma.145;293 Growth into the optic
nerve is more common with juxtapapillary tumors but retinoinvasive melanomas, which have
a tendency to invade non-adjacent retina and the optic nerve, have been described.160;279;280
3.1.2.4. Metastasis
The ability to metastasize is a characteristic of malignant tumors. Uveal melanoma
metastasizes in 45% of patients within 15 years,31;145;164;296 but individual risk is strongly
influenced by several tumor and host-related factors. Remarkable features of the metastatic
process of uveal melanoma are the purely hematogeneous dissemination from the primary
lesion (with the exception of tumors invading the conjunctiva and accessing the lymphatic
vessels there) and the overwhelming predominance of the liver as the site of metastasis. Liver
is involved in more than 90% of cases of metastatic uveal melanoma and in 33-56% it is the
only site of metastasis.44;83;89;111;145;152;224;296 Other typical metastatic sites are skin, lung, bone
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and brain.44;89;152;296 Once metastases develop, the prognosis with currently available therapies
is poor. One-year survival rates of 15-40% have been reported,87;111;145 and although current
treatments can slow down the metastatic growth, three year survival in recent studies does not
exceed 5%.87
There is much we don’t know about the metastatic process of uveal melanoma. One
key question is when the dissemination of malignant melanoma cells outside the eye takes
place.88;103;187;292  It now seems likely, based on studies of tumor doubling times, that
dissemination takes place early, even years before the primary tumor is diagnosed and
treated.48;88 Another yet unexplained feature of the metastatic uveal melanoma is the variable
and often long delay before the development of clinically detectable metastases. Metastases
are detected in approximately 1% of patients at the same time as the primary tumor,307 and the
incidence peaks 2-3 years later.145;164 But in 20% of those patients who eventually develop
metastatic disease, the onset is delayed more than 10 years,164 and cases of metastases
appearing more than 40 years after treatment of the primary tumor have been reported.59;263
3.1.3. Diagnosis
3.1.3.1. Symptoms and Signs
Uveal melanoma is usually a slow-growing tumor and the initial symptoms are often mild and
unspecific. The most common initial symptoms are blurred vision (50-69%), visual field
defect (9-30%) and photopsia (18-26%).65;86;145;222 Irritation or actual pain was reported by 6-
24% of patients,86;145;222 and these symptoms usually result from ciliary body invasion or
increase in intraocular pressure (IOP). Studies on the delay in diagnosis report that 60-87% of
patients had symptoms at diagnosis.65;86 In 25-30% of patients the diagnosis is made during a
routine examination, when at least half of them are still asymptomatic.65;86
Some uveal melanomas first present through secondary effects such as glaucoma,
sector cataract, vitreous hemorrhage or uveitis.85;204;258;316 This mode of presentation is more
typical for a ciliary body melanoma which can invade and occlude the chamber angle,
encroach on the lens and cause hemorrhage or inflammation while remaining hidden in non-
dilated fundus examination. Glaucoma secondary to uveal melanoma is more frequent with
large tumors, which can cause angle occlusion either by direct infiltration or mass effect and




Diagnostic accuracy of uveal melanoma has improved considerably in the past 30 years. A
study in 1973 reported a misdiagnosis in up to 20% of eyes enucleated because of a suspected
melanoma,259 whereas the most recent estimate by the COMS was less than 0.5%.290 It merits
notice, however, that the COMS figure is based on a data set of tumors which had a minimum
height of 1 mm and minimum largest basal diameter (LBD) of 5 mm, which excludes the
smallest and diagnostically most challenging lesions from the analysis. Nevertheless, the
present-day ophthalmologist is better equipped for making the diagnosis with new
fundusscopic examination lenses and imaging equipment such as B-scan and high-frequency
ultrasound.15;183;265 A considerable part of this success is also due to concentrating the care of
uveal melanoma patients to specialized ocular oncology centers and the wealth of experience
and understanding of the disease that has also become available due to meticulous research
and reporting by several study centers worldwide.
The diagnosis of uveal melanoma is most often based on typical appearance of the
tumor on fundus examination and B-scan ultrasound. The key clinical features are size, shape,
pigmentation, exudative retinal detachment (RD) and orange lipofuscin pigment. The interior
of the tumor often gives a low-reflectivity signature in B-scan ultrasonography. This
examination can also detect macroscopic extrascleral extensions. Tumor edges extending
anterior to ora serrata can be located using transillumination, which is also useful for detecting
melanomas in the ciliary body. The latter, however, are best visualized with high-frequency
ultrasound.99;183;184 Further confirmation can be obtained with computed tomography (CT)
and magnetic resonance imaging (MRI) of the orbit.26;61;226;265;314 Especially with atypical
lesions, such as amelanotic tumors which may resemble a choroidal metastasis, a systemic
screening for a primary tumor elsewhere is warranted.
Fluorescein angiography (FAG) has been used to identify the double circulation
pattern typical of uveal melanoma,18;288 but is seldom needed anymore except in cases where
the differential diagnosis of a vascular tumor is considered. Indocyanine green angiography
(ICG), a more recent diagnostic method254 which uses infrared light for better tissue
penetration, has been shown to be superior to FAG in imaging tumor vascularization196 and,
together with confocal digital imaging techniques, can also detect microvascular
patterns,195;197 an established prognostic indicator which was previously accessible only on
histopathologic examination of tumor tissue.
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Fine-needle aspiration biopsy (FNAB) has been used as a means of confirming an
otherwise difficult diagnosis.25;28;54;95;183;266 The biopsy can be performed either directly
through the sclera or transvitreally, under visual control. The techniques have proven to be
reasonably safe and accurate, but there has been some concern that this invasive manipulation
of tumor tissue might promote dissemination of malignant cells into the vitreous or outside
the eye. No conclusive evidence in support of these risks have been found. With the discovery
of new cytology- and genome-based prognostic factors otherwise inaccessible in eyes treated
with radiotherapy, the indications for FNAB may broaden in the future.95;183
The challenge in the diagnosis of uveal melanoma today is rarely in differentiating it
from other ocular tumors but in detecting the tumors earlier, when they are smaller. It is
unknown how early these tumors should be detected and treated to prevent metastatic spread
and thus improve survival, but it seems clear that early treatment of the consequently smaller
tumors would increase the chances of preserving the eye and visual function.3;86
Differentiation between benign choroidal naevus and a small malignant melanoma is often
challenging. One option is to observe for growth but the safety of this practice has been
questioned.13;291;292 The clinical characteristics that predict growth of a small choroidal
melanocytic lesion are the presence of symptoms, thickness over 2 mm, subretinal fluid,
presence of orange lipofuscin pigment on the tumor surface, and location touching the optic
disc. Features associated with benign behavior are drusen over the tumor and presence of
retinal pigment epithelium changes such as hyperpigmentation over and around the
tumor.247;291
3.1.3.3. Classification
Several classification systems for uveal melanomas have been suggested to be used as
prognostic tools, to help the ocular oncologist in managing and counseling the patient, and to
facilitate research and comparison of results from different centers.
In 1931, Callender published his classification system for uveal melanomas based on
the morphology of tumor cells, their nuclei and arrangement.40 Spindle A and spindle B cells
are fusiform in shape and have relatively normal nuclei with small or indistinct nucleoli. The
third cell type, called epithelioid, comprises larger, less differentiated cells with large nuclei
and prominent nucleoli. With modifications suggested by pathologists of the Armed Forces
Institute of Pathology in 1983,186 this system, which classifies uveal melanomas as spindle,
mixed, or epithelioid in the order of worsening prognosis, is still the backbone of uveal
melanoma histology. However, with increasing numbers of uveal melanomas now being
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managed conservatively with radiotherapy, histological samples are not routinely available for
the implementation of the Callender classification in clinical practice.
Classification based on tumor size, such as the initially used Warren classification
and its modifications, have been shaped by clinical conventions. A choroidal tumor less than
2-3 mm thick and under 15 mm in diameter can either be a large nevus or a small melanoma,
depending on other characteristics and documented growth. Medium-sized tumors,
consequently, were defined as those that are large enough to require active treatment instead
of mere observation but smaller than what is considered large.14;309
The threshold between a medium-sized and a large uveal melanoma, especially in
terms of height, shows great variation in the literature, ranging from 5 to 10 mm.14;81;234;249;309
Some definitions of the upper limit for the medium-sized category have been based on the
maximum tumor size eligible for conservative treatment at the time, resulting in increasingly
large tumors being re-classified as medium-sized as eye-conserving techniques evolve. Even
the COMS changed their minimum tumor height for large tumors from 8 to 10 mm mid-way
through the study period.57
In 1993, Augsburger suggested two classifications systems that would improve upon
the existing ones. In the first, the thresholds were defined to divide tumors equally between
three categories, resulting in maximum height values of 5 mm and 8 mm for small and
medium-sized tumors, respectively. In the other, height thresholds of 3 mm and 8 mm were
found to produce maximum separation of the survival curves, increasing the value of the
classification in determining prognosis.14
In the 1980s the COMS researchers introduced a new size classification for their
prospective multi-center study. They defined small melanomas as those that are 1.0 to 3.0 mm
in thickness and 5.0 to 16.0 mm in LBD.291 Medium-sized tumors were classified as those 2.5
to 10.0 mm in height and under 16.0 mm in LBD, unless the tumor was within 2.0 mm of the
optic disc, in which case the maximum height for a medium tumor was 8.0 mm.189 COMS
large tumors were those over 16.0 mm in LBD or over 8.0 or 10.0 mm in height, depending
on their proximity to the optic disc.57 Diffuse tumors, tumors with an extrascleral extension
larger than 2 mm or any iris involvement as well as those with over 50% of their bulk limited
to the ciliary body were considered ineligible for the study and thus left outside the
classification.57
The Tumor, Node, Metastasis (TNM) System is an international classification
developed in collaboration by the American Joint Committee on Cancer (AJCC) and Inter-
national Union Against Cancer (IUCC) to aid in the management, research and assessment of
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prognosis for different forms of cancer. The TNM classification for uveal melanoma has
evolved over the years and has yet to become established world wide.276;277 The current TNM
6th Edition categories T1,T2, and T3 closely follow the COMS definitions for small, medium-
sized and large, respectively.277 Extra-ocular extension is factored in subgroups for T1 and T2
tumors while large tumors with extraocular growth are classified as T4.
3.1.4. Primary Treatment
Once the diagnosis of malignant melanoma of the uvea has been made, several management
options for the primary tumor are currently available (Table 1). These include enucleation,
eye-conserving surgery, different forms of radiotherapy, and thermotherapy. The primary aim
of all treatments is to safely destroy the tumor, prevent metastatic spread and promote
survival. Conservation of the eye, avoiding ocular morbidity and retaining vision are
secondary, if important, aims.
3.1.4.1. Observation
One approach to take when faced with a uveal tumor of undetermined malignant potential is
observation. When enucleation was the only alternative, this option was easily justified for
slow-growing lesions.105 Now, with great improvement in the diagnostic accuracy of uveal
melanoma and the availability of several eye-conserving treatment options, observation is
recommended only for small lesions which are difficult to distinguish from benign nevi,
especially when the lesion is close to the fovea.227 Because both the risk of metastatic disease
and the risk of vision loss after eye-conserving treatment increase with tumor size, active
treatment should be considered when the observed lesion grows or manifests other evidence-
based high risk characteristics.247;291
3.1.4.2. Enucleation
Until the 1970s enucleation was the standard treatment for malignant melanoma of the
uvea.260;319 When alternative, eye-conserving treatment options became available over the past
30 years, enucleation has been the standard against which other options have been
measured.16;24;76 Even now, when the majority of uveal melanomas in developed countries are
managed with various eye-conserving modalities, enucleation is still a common alternative,
also in the leading centers, and recommended in cases when the disease has progressed
beyond reasonable hope of saving the eye and useful vision.67;261
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Table 1. Advantages and disadvantages of currently available primary management options for large uveal
melanomas.
Advantages Disadvantages
Enucleation • Low cost
• Easy and safe to perform
• Practically no local recurrence
• Little further management
needed




• Little or no radiation to critical
ocular tissues
• Removes necrotic tumor tissue
• Markedly less neovascular
glaucoma and optic neuropathy
• Better preservation of visual
acuity
• Comparably high risk of local
recurrence
• Requires hypotensive
anesthesia, which is safe only
for patients of good general
health
• Demanding for the surgeon
• Further vitreoretinal procedures
often necessary
Endoresection • Theoretically same advantages
as with transscleral resection but
easier and safer to perform
• Little published experience yet
• Risk of intravitreal seeding of
tumor tissue and satellite
recurrences
Brachytherapy • Safe to perform
• High eye retention rate
• Low local recurrence rate
• Intermediate costs
• Irradiation of healthy ocular
tissues proportional to tumor
height
• High ocular complication rate,
further treatment often
necessary
• Long-term retention of good VA
rare





• Safe to perform
• High eye retention rate
• Low local recurrence rate
• Sharply defined target volume
can help limit radiation
maculopathy and neuropathy
• Limited to few specially
equipped facilities
• Anterior segment complications
• Further management of ocular
complication often necessary
• Long-term retention of good VA
rare
• No tumor tissue available for
analysis
Gamma knife • Safe to perform
• High eye retention rate
• Low local recurrence rate
• Theoretically as precise as
particle beam but more widely
available
• In practice, dosimetric accuracy
not yet as good as with particle
beam
• Little published experience yet
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The advantages of enucleation are that it is easy to perform in any ocular surgery unit
and that subsequent local tumor recurrence is practically non-existent.295 It also provides
ample tumor tissue for histopathologic analysis, which is helpful for determining the systemic
prognosis of the disease and, possibly in the near future, for assigning adjuvant systemic
therapy. The downside is immediate loss of the affected eye and any visual function that was
left.190
In terms of preventing metastatic spread and thus improving survival, enucleation
has not been shown to be superior to radiotherapy or to other current eye-conserving
options.2;17;77;238;239;282 In the late 1970s McLean, Zimmerman and Foster a proposed a
hypothesis that by either direct manipulation of the tumorous eye or removal of beneficial
immunological stimulus presented by the primary tumor, enucleation may in fact promote
metastasis as compared to radiotherapy.270;320 To address this controversy, as well as other
important questions about the treatment and prognosis of uveal melanoma, the COMS was
initiated. This large, randomized, multi-center study evaluated the melanoma-specific survival
after iodine brachytherapy vs. enucleation of a medium-sized uveal melanoma and found no
difference during a 10-year follow-up.76 In a parallel study, the COMS also discovered that
pre-enucleation irradiation of a large tumor does not offer survival benefit over enucleation
alone.57;294;295
3.1.4.3. Local Transscleral Resection
Local transscleral resection of intraocular tumor tissue has been used to manage uveal
melanomas since the early 1970s.69;100;215;216 The surgery is technically demanding and
involves dissecting a scleral flap through which the tumor and a safety margin of surrounding
uvea is resected while avoiding damage to the overlying retina. In order to limit bleeding, the
procedure is done under hypotensive anesthesia, which makes it unsuitable for elderly patients
and others with poor general health. Furthermore, the initial published series reported high
rates of local tumor recurrence.71 Subsequent reports have shown that administering adjuvant
radiotherapy, e.g. with a ruthenium-106 plaque placed over the resection area after surgery,
markedly improves local control and such adjuvant therapy is currently recommended as
standard.63
Reports of local transscleral resection show promising preservation of visual acuity
even when the tumor is large enough to be associated with considerable ocular morbidity after
radiotherapy.27;67;70;158 When used in conjunction with adjuvant plaque brachytherapy, doses
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to adjacent ocular tissues are small compared to those associated with irradiation of the whole
tumor volume by stand-alone radiotherapy. Furthermore, by removing the intraocular tumor
mass, resection may help the eye to return to a more physiological state resulting in a lower
incidence of neovascular glaucoma.27;158 The disadvantage of local resection, even with
routine use of adjuvant radiotherapy, is local tumor recurrence which is more common after
resection than after primary radiotherapy.158
3.1.4.4. Endoresection
Endoresection, as described by Damato et al,66 was developed for peripapillary uveal
melanomas in patients for whom the preservation of vision in the tumor eye is of high
priority. This technique, which involves vitrectomy followed by transretinal resection of the
tumor mass with a vitreous cutter, has been controversial because of the fear that the
piecemeal removal of tumor tissue may lead to intraocular dissemination of viable tumor cells
and increased tumor recurrence.123 Endoresection has also been used to remove tumors first
managed by primary radiotherapy in an attempt to reduce complications related to the
presence of a necrotic tumor mass.29;33
3.1.4.5. Laser Photocoagulation and Transpupillary Thermotherapy
Laser photocoagulation was preceded by xenon arc photocoagulation and has multiple uses in
general ophthalmology. It has been used as a stand-alone therapy for small uveal melanomas,
as a supplementary therapy in combination with irradiation, and as additional treatment for
small marginal recurrences after radiotherapy.22;178;192;264;304 In histopathological examination
of photocoagulated tumors, the necrosis caused by a single treatment session penetrates less
than 1 mm into the tumor and many tumors showed only partial or no necrosis after
completed therapy. Laser photocoagulation is hence considered inadequate as a stand-alone
therapy even for the smallest of uveal melanomas.7;82
Introduced in 1995, transpupillary thermotherapy (TTT) employs an infrared diode
laser, which is aimed through a dilated pupil using a large spot size of 2-3 mm and an
exposure time of 1 minute.149;150;205;206;228;251;253 This causes irreversible cellular damage at
sub-coagulation level with penetration of up to 6 mm into the tumor. The peak temperature of
the heated tissue is lower, 45-65°C, and it builds up more slowly than in laser
photocoagulation. Laser power required to achieve the desired effect depends on tumor




TTT has proven to be a well tolerated and effective treatment for retinal
hemangiomas104;225 as well as small retinoblastomas1;177;250 but its effectiveness as a
standalone treatment of uveal melanoma has been questioned. In particular, melanoma cells
invading the overlying sclera may escape destruction because current TTT is unable to
equally elevate the temperature of the pigmented tumor and lightly pigmented sclera. As a
solution, a so-called sandwich therapy combining TTT with reduced-dose plaque
brachytherapy has been investigated.206;244 The maximum tumor height recommended for
TTT alone is 4 mm whereas tumors up to 8 mm have been managed with the sandwich
technique. Reported side-effects typical of TTT include branch retinal vessel obstruction and
deep scotomas in areas where the nerve fiber layer of the retina has been damaged.228;251;253;313
In terms of ocular morbidity and preservation of visual function, TTT has not been shown to
offer any advantage over plaque brachytherapy.129
3.1.4.6. Plaque Brachytherapy
Brachytherapy is defined as radiotherapy in which the radioactive sources are placed near or
within the tumor. In 1929, Moore managed a malignant uveal melanoma by surgically
implanting radioactive radon seeds within the tumor tissue.194 In the following decades,
Stallard281 and his contemporaries further developed brachytherapy of ocular tumors into its
current form: concave plaques containing a radiation source, which are sutured onto the
external scleral surface next to the tumor for a pre-calculated time.210
The tumor is localized during surgery with transillumination, indirect ophthalmo-
scopy with scleral indentation, or both. After peritomy, a non-active dummy plaque is first
placed on the sclera to verify accurate positioning. If necessary, one or more ocular muscles
are deinserted if their insertions interfere with plaque placement. Transillumination can be
used to check that the plaque covers the whole tumor, usually with up to 2 mm of safety
margin on all sides. Scleral sutures are then placed to fix the plaque using its suture holes and
the dummy plaque is then replaced with an active one.
Several radionuclides have been used in ophthalmic brachytherapy (Table 2). The
first isotope that saw general use in the treatment of uveal melanoma was cobalt-60, a high-
energy isotope emitting both gamma and beta radiation and with a half-life of 5.2 years.262
The high energy (1.3 MeV) radiation released from this isotope is not adequately blocked by
the metal plaque, which causes unnecessary irradiation to orbital tissues as well as safety
concerns to medical personnel administering the treatment.144 Cobalt-60 brachytherapy also
delivers more radiation to healthy ocular tissues and more radiation-related complications
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were observed52;211 than with low-energy gamma-emitters such as iodine-125 (27-35 keV)
and palladium-103 (21 keV), which have replaced cobalt in ocular brachytherapy. Of these,
iodine-125 is currently the most commonly used, and well documented in the
literature.47;76;131;143;210;212;229 Few centers use palladium-103, but available reports indicate
that its lower energy may yield more favorable dose distribution and fewer complications than
iodine-125.92;93 Iridium-192 is another less often used option in brachytherapy, which
resembles Cobalt-60 in that it produces both gamma and beta rays but with half the maximum
energy.120;299
Ruthenium-106 is a beta-emitter with high energy (293 keV), and low tissue
penetration. As such, it is well suited for the treatment of small and medium-sized uveal
melanomas with heights of 5 mm or less. Ruthenium brachytherapy was introduced in 1964
by Lommatzsch and Vollmar and has been well documented over the past
decades.38;174;175;217;243 Strontium-90 is another beta-emitter with high activity resulting in a
high dose rate and short application time. Reports suggest that strontium is as effective and at
least as well tolerated as ruthenium.193;302 A recent report also describes a bi-nuclide
applicator which combines iodine with ruthenium in order to manage thicker tumors than
what is possible with ruthenium alone but with a smaller dose delivered outside the target
volume compared to iodine.94
Brachytherapy plaques are most often rounded, made of gold (iodine), platinum, or
silver (ruthenium) and come in several diameters in order to effectively treat tumors of
different size.154;201;210 Some plaques have a notch for the limbus or for the optic nerve so that
the plaque can be placed adjacent to these structures. Some plaques have a collimating rim in
Table 2. Radionuclides used in ophthalmic brachytherapy
Nuclide Symbol Type Energy Half-Life Introduced* Max Height†
Cobalt Co-60 Gamma / Beta 1.3 MeV / 320 keV 5.2 years 1948
Ruthenium Ru-106 Beta 293 keV 373 days 1964 5 mm
Iodine I-125 Gamma 27-35keV 60 days 1975
Strontium Sr-90 Beta 546 keV 29 years 1983 5 mm
Iridium Ir-192 Gamma / Beta 600 keV / 370 keV 74 days 1983
Palladium Pd-103 Gamma 21 keV 17 days‡ 1986
* First reported period of use in ophthalmology
† Maximum tumor height that can be safely managed in one application
‡ The actual half-life of Pd-103 is 50 days but the energy emission drops dramatically after 17 days
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order to limit the lateral scatter of irradiation whereas others place the seeds in individual
collimating slots.11;133 While many ocular oncology centers have adopted the COMS plaques,
many others have their own plaque designs, which vary greatly in the positioning and number
of radioactive seeds. In some plaques the number and position of the radioactive seeds can be
adjusted to suit individual tumor shapes and to minimize irradiation of critical ocular tissues.
Such an individually customized treatment plan is also known as conformal
brachytherapy.12;162;202 In the past decade, computer-based brachytherapy planning software
have become available which greatly help in the accurate planning and customizing of
treatment.10;162;209
Plaque brachytherapy is currently the most common treatment option for uveal
melanoma. It offers good chances of conserving the eye, often with at least some useful
vision.49;189;212 The procedure is relatively easy and safe to perform on almost any patient and
the costs are reasonable. The main disadvantage of brachytherapy is the less sharply defined
intraocular dose distribution compared to charged particle radiation, which limits the ability to
shield healthy ocular tissues from radiation. Risk of local recurrence is also higher than after
enucleation but lower than after local resection and TTT.
3.1.4.7. Charged Particle Irradiation
Proton beam114;117;241 and helium ion46;47;172 irradiation, collectively known as charged particle
radiation, have been used since the late 1970s as a means to destroy intraocular tumors. Both
methods require the use of a cyclotron to produce the particles, which, at the end of their
range, release energy through interactions with electrons in the medium. The range at and
over which most of the energy is released can be controlled by modulating the energy of the
particles.109 This phenomenon is known as the Bragg peak effect which, in combination with
collimators adjusting the cross-section of the particle beam, makes it possible to sharply
define the three-dimensional field of radiation and place it over the tumor while sparing
surrounding intraocular tissues. Accurate placement is facilitated with detailed three-
dimensional computerized treatment planning and radio-opaque tantalum rings sutured onto
the scleral surface.
The main advantage of charged particle radiation over brachytherapy is the more
controllable intraocular dose distribution which enables all parts of the tumor to receive equal
doses of radiation while sparing the radiation-sensitive vital ocular structures. In theory, this
advantage becomes more pronounced with increasing tumor size.114 The disadvantage of
charged particle therapy, in addition to being limited to facilities with access to a nuclear
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accelerator, is the increased incidence of anterior segment complications, such as
keratoconjuctivitis sicca, loss of eyelashes, and depigmentation of skin in dark
individuals.55;140 Reports of ocular morbidity and preservation of vision comparing
brachytherapy with charged particle radiation in the treatment of patients with tumors of
various sizes, show no clear advantage in favor of either method,55;139;312 although some
individual patients, e.g. those with a tumor which is located adjacent to the optic disc or an
awkwardly shaped tumors in the iris or ciliary body, may benefit from the more sharply
limited treatment field of charged particle radiation.
3.1.4.8. Stereotactic Radiotherapy
Stereotactic radiotherapy, also called stereotactic radiosurgery, was first envisioned by
Leksell in the 1960s to manage intracranial tumors. The principle is to accurately map the
location and shape of the lesion in three dimensions and then direct several collimated beams
of gamma radiation from multiple radiation sources to converge in that exact target volume.
With the evolution in the accuracy of three-dimensional imaging, tumor volumes as small as
medium to large size uveal melanomas have been managed with the Leksell Gamma Knife
since the mid-90s.181;198;199 The advantages and disadvantages are similar to those of the
charged particle therapy: target volume can be relatively sharply defined to spare adjacent
healthy tissues but, in spite of this, anterior segment complications such as dry eye and
neovascular glaucoma are still an issue. Furthermore, for the same level of dose conformation,
the stereotactic approach requires more beams to be coordinated than in charged particle
radiotherapy, which results in increased treatment time, lower dose rate and more challenges
in immobilizing the eye for the treatment.311
3.1.5. Treatment and Prognosis of a Large Uveal Melanoma
3.1.5.1. Choice of Primary Treatment
Until quite recently, most authors recommended enucleation for large uveal melanomas. This
has been justified by the fear of increased local recurrence and of uncontrollable side-effects
resulting from radiotherapy of large intraocular tumor volume. There is subsequent paucity in
studies that systematically evaluate an eye-conservative approach for large uveal melanomas,
or prospectively compare two alternative methods. There is also a lack of a universally
implemented staging system for tumor size, resulting in the aforementioned variability in the
definition of a large tumor.
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The most important study of large uveal melanomas is undoubtedly the COMS Large
Tumor Study which randomized patients for enucleation with or without pre-enucleation
irradiation.57;130;294-296 Although lacking a conservative treatment arm, the study has provided
useful survival data for this group of patients. Of the conservative treatment options,
stereotactic surgery,198 plaque brachytherapy,249 and transscleral local resection27;158 have also
been evaluated specifically for large tumors. In addition to these, studies of mainly medium-
sized tumors managed with proton beams,102 helium ions,50;55 and plaque brachytherapy with
various isotopes97;118;119;219 have included large tumors and provided some insight into the
outcome for these patients.
3.1.5.2. Local Tumor Recurrence
Local tumor recurrence, unlike disease-specific mortality, is known to depend on the primary
treatment method and enucleation is still the most effective way to ensure local control.
Reports comparing two eye-conserving treatments for patients with variable-sized tumors
indicate less recurrence after plaque brachytherapy than local resection, and possibly less still
after charged particle radiation.27;55;312 Large tumor size and posterior location are also known
risk factors for recurrence.71;143;151;220 Local recurrence after radiotherapy has been associated
with increased risk of melanoma metastasis and mortality in some studies,79;112;128;283;305
although this association has not been strong or detectable in others.20;143
Studies of predominantly medium-sized tumors managed with plaque radiotherapy
have reported 5-year incidences of local tumor recurrence ranging from 6% to
15%.55;118;119;151;212;219 The COMS medium tumor study reported 10.3% risk of treatment
failure at 5 years,143 and in the few reported series consisting solely of large tumors, the
respective incidence has not been higher than this, ranging from 6% to 9%.27;158;249
3.1.5.3. Metastasis and Survival
Uveal melanoma is a potentially fatal disease. Large tumor size is known to be associated
with worse prognosis.164;185;235 Increasing evidence suggests that dissemination of the disease
outside the eye takes place years before the diagnosis of a large melanoma,48;88 in which case
the primary treatment has little effect on survival provided local control is achieved. This
hypothesis is supported by several studies comparing two treatments for patients with tumors
of variable size,2;17;21;24;55 as well as by the 10-year mortality findings of the COMS large
tumor study, in which the histopathologically confirmed melanoma-specific mortality was
Review of Literature
31
40% and 45% in enucleation and pre-enucleation irradiation arms, respectively,130 and 64% of
patients were diagnosed as having metastasis within 6 years.296
A population-based study by Kujala et al of the very long term prognosis of uveal
melanoma in patients managed with enucleation reported 64% and 58% melanoma-specific
mortality at 15 years for a subgroup of tumors with LBD ≥16 mm using the Kaplan-Meier and
cumulative incidence methods, respectively.164 Another study, which defined a large tumor as
≥8 mm in height, reported 30% and 55% metastasis rates at 5 and 10 years, respectively,
using the Kaplan-Meier method.249
3.1.5.4. Visual Function
One of the toughest challenges during the four-decade long history of eye-conserving
treatment for uveal melanoma has been preservation of the functionality of the saved eye. Not
only the disturbance caused by the intraocular tumor but also the trauma to healthy tissues
resulting from surgery or radiotherapy threatens the delicate function of the eye.
Defining and reporting the visual outcome of eye-conserving therapy is not a simple
task, either, and varies from one center to another. Some researchers have measured vision
loss as the number of Snellen lines lost compared to baseline acuity whereas others use the
loss of certain VA levels as end points for their study. The most commonly used VA levels in
North American centers are 20/40 and 20/200, which correspond to low vision and legal
blindness, respectively. The World Health Organization (WHO) defines low vision as 20/70
or lower and blindness (loss of ambulatory vision) as 20/400 or less.
The statistical analysis of vision loss is made more complicated still by the fortunate
fact that some patients who first experience loss of a VA level subsequently regain vision –
and possibly lose it again later when delayed complications set in.
Currently, the chances of preserving vision are good for small uveal melanomas
located at a sufficient distance from the macula and the optic disc. What is considered
sufficient distance depends on tumor thickness and the chosen treatment option. With
increasing tumor size and decreasing distance to the posterior pole, the prognosis for saving
the vision becomes worse.50;60;108;173;189;284 In the COMS medium tumor study, the 5-year
Kaplan-Meier estimate for loss of 20/200 vision was 43%, and the thickest tumors and those
closest to the foveal avascular zone had the worst mean VA in stratified analysis.189 In a
randomized study comparing helium ion irradiation and iodine brachytherapy, the proportion
of patients who had lost 20/400 vision at the last follow-up were 46.5% and 52.0%,
respectively.55 After proton beam irradiation of a large series of melanomas in one center, the
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5-year incidence of loss of 20/200 VA varied from 10% in the very lowest risk group to over
90% in the highest risk group.108 The main risk factors in that study were distance less than 2
mm from either the macula, the optic disc, or both, tumor height, visual acuity at baseline and
retinal detachment. A study of large tumors, defined as thicker than 8 mm, reported that the
Kaplan-Meier estimate for loss of 20/200 VA was 57% at 5 years and 89% at 10 years. Two
series that compared iodine brachytherapy with local transscleral resection for large uveal
melanomas noted that more than 90% of treated eyes eventually lost 20/200 acuity after
brachytherapy whereas 50-60% retained this VA level at least for 5 years after TSR.27;158
3.1.5.5. Conservation of the Eye
Failure of the eye-conserving approach results in secondary enucleation of the tumor eye. The
most common causes for enucleation after radiotherapy of a uveal melanoma are local tumor
recurrence and intractable treatment complications which cause either discomfort and
blindness of the tumor eye or loss of fundus visibility required for safe follow-up of the
tumor.78;108;143;256 Some centers  readily enucleate, as a safety measure, eyes which have lost
usable vision whereas others strive to retain all asymptomatic eyes in which the tumor has
regressed satisfactorily. The difference in the indications of secondary enucleation
complicates the comparison of eye retention rates between centers and introduces bias in the
reported incidence of complications and local tumor recurrence: in centers where enucleation
is more readily performed, incidences of complications and recurrence appear to be smaller. A
recent retrospective study suggests that secondary enucleation of a blind eye after plaque
brachytherapy is unlikely to improve melanoma-specific survival.20
In the COMS medium tumor study, the 5-year Kaplan-Meier estimate for eye
retention was 87.5%,143 and in a large retrospective analysis of tumors of all sizes managed
with a multimodality approach in a single center the rate was 88.9%.67 A prospective
randomized study comparing iodine brachytherapy and helium ion radiation reported 5-year
ocular retention rates of 82.7% and 90.7%, respectively.55 Ocular retention rates similar to
these have been reported for other series of mainly medium-sized tumors, with comparable
results after brachytherapy and charged particle irradiation.108;119;312 In the few series
consisting of large uveal melanomas and in high-risk patient subgroups of series with variable
tumor size, 5-year ocular preservation rates as low as 75% have been noted.102;108;249
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3.2. Radiotherapy of Uveal Melanoma
3.2.1. Biological Effects of Radiotherapy
The effect of any ionizing radiation, whether alpha, beta, gamma, or charged particles, on
living cells is caused by disruption of the DNA strands of the chromosomes, resulting in
dysfunction of reading the genetic code and of producing key proteins, and ultimately, if the
damage is severe enough, in cell death. The radiosensitivity of different cell types and
subsequently of different tissues varies considerably because of differences in cell cycling
rates and capacity to repair damaged DNA. In general, tissues with rapidly reproducing cells
such as intestinal mucosa and hematopoietic tissue in bone marrow are the most sensitive and
cells with little or no reproductive capacity such as nerve cells and retinal photoreceptors are
less sensitive. Even the least sensitive tissues are, however, subject to radiation damage
because their blood supply is dependent on vascular endothelial cells of nearby vessels, which
are relatively sensitive to radiation. Tumors also vary greatly in their ability to withstand
radiation damage, with uveal melanoma being, unfortunately, one of the least sensitive. It has
also been shown that different lines of uveal melanoma cells differ in sensitivity to
radiation.156;278;301
3.2.2. Dose and Dose Rate
The unit of absorbed dose of radiation is 1 Gray (Gy), which equals 1 Joule per 1 kilogram. In
brachytherapy this dose is delivered during a precalculated, continuous time period whereas
charged particle radiation is usually given in several fractions, the total dose of which is
measured in cobalt-Grey equivalents (CGE = proton dose in Gy * radiobiological
effectiveness, 1.1 for protons and 1.3 for helium ions). In brachytherapy, the dose delivered to
a certain point within the eye during a certain treatment period is directly proportional to its
depth or the distance from the radioactive plaque. Hence, in brachytherapy, the sclera and
tumor base receive many times the dose prescribed to tumor apex, and this difference
increases with increasing tumor height. In contrast, charged particle radiation delivers a more
or less uniform dose to all of the tumor mass.
The smallest dose guaranteed to kill uveal melanoma cells in vivo is not known.
Stallard selected a dose of 100 Gy prescribed to the apex of the tumor,281 after which others
have reported series managed with smaller apical doses, ranging between 70 and 85
Gy.97;210;220;231;267 The COMS medium tumor study used I-125 brachytherapy with
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prescription dose of 85 Gy to the tumor apex if the tumor was more than 5 mm in height or, in
the case of smaller tumors, 85 Gy prescribed to depth of 5 mm,189 a guideline also endorsed
by the American Brachytherapy Association (ABS).201 The COMS later reported an
association between lower apical dose and local failure within that dose range.143 Gragoudas
et al reported a randomized series of uveal melanomas managed with lowered-dose proton
beam irradiation of 50 CGE. During the 5-year follow-up they observed no ill effects in terms
of recurrence and metastasis nor a clear improvement in avoiding complications and ocular
morbidity.115 In the treatment of skin melanomas, doses lower than 50 Gy have been
associated with a considerable risk of local failure.207
In addition to total dose delivered to the tumor, the rate at which it is delivered has an
effect on the biological effectiveness of the treatment. This is because the DNA strand has
two chains, one or both of which can be severed by a strike from an ionizing particle. If both
are severed in a single hit, the molecule is inactivated immediately. If only one strand is
severed, the result depends on whether the cell can repair this sub-lethal damage before a
second hit takes out the remaining strand, and here the frequency at which these hits occur
becomes a factor. The combination of single-hit and sub-lethal damage to tumor tissue can be
successfully approximated with a mathematical model called the linear-quadratic (LQ)
equation. The dose rate range at which the dose rate effect can be observed ranges from 10 to
1000 cGy/h. At higher dose rates, no additional biological effectiveness is achieved whereas
at lower dose rates the repair of sub-lethal damage catches up with the damage caused,
leading to steady-state systems in which linear dose-dependent single-hit damage
predominates.125 Tissues also differ in their capacity to repair the sub-lethal damage, which
can be taken into account in the model by using appropriate α/β-ratios determined
empirically.233;300 On this basis, tissues are divided into early-reacting, which are more
capable of repairing sub-lethal damage and late-reacting, which are thought to be more
susceptible to higher dose rates.126
The relevance of the dose rate effect in the management of uveal melanoma is two-
fold. In theory, treatment given with a higher dose rate is more likely to completely destroy
the tumor and should improve local control, as has been observed in both animal315 and
clinical219 studies. However, the late-reacting normal tissues of the eye are likely to be even
more sensitive to the increased dose rate, which results in more ocular morbidity, which has
also been noted in several studies.6;36;119;148;219;315
The optimal dose rate for the treatment of uveal melanoma is yet to be defined. The
COMS brachytherapy protocol allows dose rates from 42 to 105 cGy/h at the tumor apex,189
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whereas the current ABS recommendations suggest a dose rate between 60 to 105 cGy/h. An
apical dose rate less than 70 cGy/h was associated with an 8-fold increase in the incidence of
local tumor recurrence as compared to tumors that received this dose rate level in a study of
150 small to medium-sized melanomas.219 On the other hand, series with lower or more
variable dose rate ranges have also shown adequate local tumor control.97;148;249;267
3.2.3. Ocular Complications of Radiotherapy
3.2.3.1. Cataract
The sensitivity of the crystalline lens to ionizing radiation is well docu-
mented.113;132;161;179;188;233;285 The onset and degree of lens opacity developing after
radiotherapy have both been shown to be dose-dependent with a maximum tolerated threshold
dose around 10-16 Gy.113;132;191 The incidence of cataract after radiotherapy of a uveal
melanoma depends on the size and location of the tumor as well as the source of radiation
used. With charged particle radiation, the incidence is strongly associated to the extent to
which the lens is located in the path of the particle beam,51;113;188 whereas greater height and a
more anterior location of the tumor are risk factors for cataract after plaque
brachytherapy.90;161;285
Char et al reported significant cataract in 22% and 25% of patients with mainly
posterior melanomas of variable size, randomized for iodine-125 brachytherapy and helium
ion radiation, respectively.55 Incidences from 48% to 86% have been reported for data sets
with anterior90;91;118 and large tumors.249 Reports of cataract extraction after radiotherapy of a
uveal melanoma indicate it to be a safe procedure.110;220;306
3.2.3.2. Iris Neovascularization and Neovascular Glaucoma
Unlike cataract, neovascular glaucoma (NVG) often causes profound and irreversible loss of
vision. This complication can also cause intractable pain in the blinded eye and require a
secondary enucleation.78;256 The mechanisms leading to iris neovascularization and
subsequent NVG after radiotherapy of a uveal melanoma are not fully understood. Evidence
suggests that large tumor size, anterior location of the tumor,75;78;98;117;155;172 and chronic
retinal detachment98 are associated with a higher risk for this complication.
A considerably higher incidence of NVG was noted after brachytherapy of
melanomas of similar characteristics compared to local resection27;158 which indicates that
either radiation damage or the presence of the necrotic tumor mass, or both, are associated
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with neovascularization. The form in which radiotherapy is administered may also have an
effect. In a randomized study of posterior melanomas, NVG occurred in 29% of patients after
helium ion radiotherapy and 11% after iodine brachytherapy.55 A similar difference of 2.1%
vs. 5.7% has been reported in a different data set comparing iodine brachytherapy with proton
beam irradiation, respectively.312 Size appears to be the strongest predictor with incidences of
up to 33-48% reported after iodine brachytherapy of large-sized tumors.27;158
Glaucoma can also develop in untreated eyes with uveal melanoma.42 In 1963,
Jensen reported glaucoma of any type in 36% of the 202 uveal melanoma patients in his data
set and that glaucoma was associated with tumor size and retinal detachment.258 In 1987,
Shields et al reported a lower incidence of 3% in their data set of 2111 melanoma patients,
and that the leading type of pre-treatment glaucoma in choroidal melanomas was
neovascular.258
Neovascular glaucoma can be managed with medication or by cyclophoto-
coagulation,142 but filtration surgery is generally not recommended for an eye with a uveal
melanoma. Panretinal photocoagulation has been suggested both as a preventive measure and
treatment.23;108;117;155 Nevertheless, NVG is the leading cause of secondary enucleation of eyes
in which successful local control was achieved with radiotherapy.78;108;200;256
3.2.3.3. Radiation Retinopathy
Radiation retinopathy is not uncommon after radiotherapy of posterior uveal melanomas and
is a potential cause of severe vision loss.90;116;120;122;249 Some degree of macular damage has
been observed in up to 89% of patients with paramacular tumors.122 Retina directly over the
tumor and thus inside the 100% isodose volume usually undergoes total atrophy.163;232 The
clinical picture of radiation retinopathy outside the treated area includes macular edema,
intraretinal microvascular abnormalities (IRMA) and capillary non-perfusion.8;37;122 These
changes have been confirmed in histopathological studies8 and are similar to those observed
in diabetic retinopathy, particularly ischemic maculopathy.
An association between radiation dose to the posterior pole and radiation retinopathy
has been documented.90;116;120;308 Gragoudas et al noted that any exposure was associated with
increased risk of this complication after proton beam radiotherapy, and that above 40 Gy the
risk no longer increased with increasing dose.116 The risk of retinopathy thus exists with any
radiotherapy but should be lower for patients with more anterior tumors90;120 and for tumors
small enough to be managed with Ru-106 and located further than 2-3 mm from the
macula.285 On the other hand, patients with diabetes seem to be at higher risk for this
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complication, possibly due to already compromised retinal vasculature.8;116;303 Although some
degree of spontaneous repair of radiation damage to retinal vasculature is known to take
place, and laser photocoagulation alone or in combination with intravitreal triamsinolone have
been investigated as a therapy for radiation retinopathy,141;157;248 long-term improvement of
vision has not been documented.
3.2.3.4. Radiation Optic Neuropathy
Like radiation retinopathy, radiation optic neuropathy is a known complication of
radiotherapy of a posterior uveal melanoma and capable of causing profound and irreversible
loss of vision.36;73;116;153;176 The risk has been associated with radiation dose to the optic nerve,
and clinical studies have suggested a tolerance threshold between 30 and 50 Gy.116;147;167;176
Not surprisingly, tumors directly adjacent to the optic nerve are associated with high (52-
66%) probability of developing severe optic neuropathy after plaque brachytherapy,73;176 with
partial optic atrophy reported in 82% after 10 years.176 A risk approaching 100% was reported
after proton beam irradiation when the optic nerve received the full therapeutic dose of 70
CGE.116 The risk is considerably smaller for anterior tumors. No practical treatment for
radiation injury of the optic nerve is currently available. Anecdotal reports exist of the
benefits of hyperbaric oxygen, if administered within days of the onset of neuropathy.34;121
3.2.3.5. Retinal Detachment
Some degree of exudative retinal detachment (RD) is detected in up to 75% of patients at the
diagnosis of uveal melanoma.159;317 The COMS reported RD at diagnosis in 56% and 81% of
patients in their medium and large tumor studies, respectively.57;189 The detachment often
resolves in the first 6 months following radiotherapy, although in some cases it may
temporarily increase possibly due to inflammation in the irradiated tumor or vascular
damage.127 Persisting or recurring RD after radiotherapy is a threat to visual function and may
require secondary enucleation either by causing loss of fundus visibility required for safe
follow-up of the tumor or by contributing to the development of neovascular glaucoma.78;98;143
Persisting or progressing exudative RD is also linked to activity of a residual
tumor.35;105;127;257 The exact mechanisms causing exudative RD postoperatively are not yet
understood. The complication is strongly associated with tumor size, posterior location, and
also with presence of microvascular loops and networks.145;159 It has been suggested that
tumor size may be a surrogate variable representing a more dense and complex vascular
system58 as well as the disturbance caused to normal choriocapillaris by a large tumor.
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The means to treat persistent exudative RD after radiotherapy are limited. According
to one case report, a progressive exudative RD after Ru-106 brachytherapy successfully
resolved after vitrectomy and drainage of subretinal fluid,221 but concerns exist about the
safety of posterior segment surgery in eyes with uveal melanomas. A small series of planned
laser-induced hypertermia in conjunction with proton beam therapy indicated a more rapid
resolution of RD than proton radiation alone,45 whereas another report suggested
endoresection after radiotherapy to limit the problems arising from the necrotic tumor mass.29
3.2.3.6. Vitreous Hemorrhage
Vitreous hemorrhage is detected in 3-9% of eyes at the diagnosis of a uveal
melanoma.57;101;145 This complication is linked to the perforation of the Bruch’s membrane,
which often results in the typical mushroom or collar-button shape and subsequent invasion
and erosion of the overlying retina.119;145;146 Bleeding from the dying tumor after radiotherapy,
if severe, can complicate the safe monitoring of tumor regression and warrant secondary
enucleation. Post-radiation vitreous hemorrhage has been reported in 9-29% of patients
managed with various forms of radiotherapy,55;118;119;212;220;285 with the lowest incidence in a
series of anterior tumors with ciliary body involvement. In a randomized study, vitreous
hemorrhage occurred in 29.6% and 19.8% after iodine brachytherapy and helium ion
radiation, respectively; the difference was not statistically significant.55 Vitreous hemorrage is
seldom the sole or the most vision-limiting complication present in irradiated eyes. Although
clearing the vitreous by vitrectomy in such cases is possible, little evidence of the usefulness
or safety of such a procedure in eyes with a malignant melanoma exists.
3.2.3.7. Complications of the Ocular Adnexa
Dry eye, depigmentation of the eyelid skin, punctal occlusion leading to epiphora, and loss of
eyelashes have been described after particle beam and other external radiotherapy of uveal
melanoma.39;55;139;179 These complications are rare or non-existent with plaque
brachytherapy55;91 and can often be limited by careful treatment planning in particle beam
therapy as well.139
Disturbances of ocular motility and muscle balance have been described after plaque
brachytherapy, resulting from tissue trauma, muscle disinsertion and low post-treatment
visual acuity.165;242 These disturbances manifest most often as exo- or hypertropia, rarely
result in long-term diplopia, but can cause cosmetic concern.
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4. Aims of the Present Study
The aim of this study was to evaluate the safety, efficacy and tolerability of iodine-125
episcleral plaque brachytherapy (IBT) as a primary treatment for a population-based,
consecutive group of patients with uveal melanomas that were large by the Collaborative
Ocular Melanoma Study (COMS) criteria. The study was designed to assess:
• Safety, in terms of survival and local tumor control. (I)
• Efficacy in conserving the tumor eye with normal cosmetic appearance and retaining
useful vision. (I)
• The incidence of side-effects and their independent risk factors. (II)
• The role of radiation dose and dose rate delivered to intraocular tissues in the
development of side-effects and loss of vision. (III)
• Potential for improving the outcome for these patients by
a) shielding intraocular structures from scattered radiation (III)
b) managing patients whose tumors are classified large because of their height with
transscleral local resection instead of IBT (IV).
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5. Patients and Methods
5.1. Eligibility Criteria and Enrolment
5.1.1. Studies I-III
Eligible to these studies were patients who were diagnosed with a uveal melanoma that met
the COMS criteria of a large tumor (largest basal diameter [LBD] >16.0 mm and height >2.0
mm, height >10.0 mm regardless of LBD, or a peripapillary tumor >8.0 mm by height and
located <2.0 mm of the optic disc)57 and managed with primary iodine-125 plaque
brachytherapy (IBT). The LBD and tumor location were determined primarily by indirect
ophtalmoscopy, B-scan ultrasonography and, in selected cases, CT or MRI. Tumor height was
based on A- and B-scan ultrasonography.
Analogous to COMS, the patient was ineligible if the tumor involved the iris, if more
than 50% of it was located in the ciliary body, if it was diffuse, ring or multifocal in type, or if
it had an extrascleral extension of 2.0 mm or more. Also ineligible were patients who had had
other treatment for their uveal melanoma before IBT. To enhance generalizability, patients
were not considered ineligible if they had a history of other coexisting disease that threatened
survival, another cancer or metastatic melanoma at the time of diagnosis, provided that
treatment was otherwise indicated.
The study period began on November 1, 1990, and ended on June 1, 2001. The files
of the Ocular Oncology Service, Department of Ophthalmology, Helsinki University Central
Hospital, a tertiary referral center which managed 90% of uveal melanomas in Finland during
the study period, were reviewed. Within the period a total of 123 patients with a large uveal
melanoma were identified, of whom 26 were managed by methods other than IBT: 13 with
cobalt and ruthenium brachytherapy at a time when indications for IBT were evolving, one
with proton beams (in Clatterbridge, UK), and 12 with primary enucleation. One patient
requested primary enucleation, four tumors could not be covered with the largest
brachytherapy plaque, three had caused extensive retinal detachment and iris
neovascularization, which indicated poor prognosis for saving the eye, and two had caused a
hemorrhagic choroidal detachment with or without subretinal hemorrhage, which made it
impossible to place the plaque accurately and also greatly worsened the prognosis for saving
the eye. One elderly patient initially refused treatment, and the eye was enucleated after the
tumor had extended outside the globe. Consequently, 97 of the 123 patients underwent IBT as
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primary treatment for a large uveal melanoma and were enrolled (Fig.2). One of them had an
extrascleral extension noted at the time of plaque insertion, and enucleation was performed
instead. In accordance with the intention-to-treat principle this patient was included in the
Study I but excluded from Studies II-III, which focused on the effects of radiation and used
per protocol analyses (Fig.2).
5.1.2. Study IV
Eligible to the study were patients with a uveal melanoma that met the COMS criteria of a
large tumor solely because of tumor height (LBD 16.0 mm and height >10.0 mm or >8.0
mm if the tumor was peripapillary),57 managed with either TSR by a single surgeon or with
IBT. The accrual period was from November 1, 1990 to June 1, 2003. TSR was performed at
the St. Paul’s Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom,
and IBT at the Department of Ophthalmology, Helsinki University Central Hospital, Helsinki,
Finland. Other criteria were similar to Studies I-III.
In Helsinki, 31 new cases of large uveal melanoma were diagnosed after the accrual
154 consecutive patients in Helsinki
with a COMS Large melanoma





648 patients in Liverpool
and Glasgow
with a COMS Large melanoma
diagnosed between November
1990 and June 2003
96 managed with IBT
1 intended IBT converted to enucleation
Population for Study I =97









46   8
=54 patients with a melanoma
that was large by height (LBD≤16
mm)
IBT population for Study IV
118 managed with TSR
(with or without RuBT)
33 (20 with adjunctive RuBT)
patients with a melanoma that
was large by height (LBD≤16
mm)
TSR population for Study IV
452 enucleation
 38  proton beam
 19  brachytherapy
  5   endoresection
  4   observation
 12  unspecified
Figure 2. Diagram of the patient populations in the four parts of the study as well as the number of the patients
managed by means other than iodine brachytherapy (IBT) and transscleral local resection (TSR) in the study
centers during the study period.
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period of the first three studies: 21 managed with IBT, four with ruthenium brachytherapy
(RuBT) and six with primary enucleation. Of the 118 patients managed with IBT, 54 met the
criteria for Study IV and were enrolled. In the UK, 118 patients with a COMS large mela-
noma were managed with TSR during this period, of which 33 met the study criteria (Fig.2).
5.2. Elements of Informed Consent
The first Finnish patients in this study were managed with IBT because they refused primary
enucleation. Encouraged by the outcome, ocular oncologists in Helsinki subsequently
informed all patients with a large uveal melanoma, in accordance with the Act of Patients’
Rights (1992/785), that two treatments were available: primary enucleation and IBT, followed
by secondary enucleation should a local recurrence or intractable complications from
irradiation develop. The patients were then informed that local recurrence after enucleation
was unlikely, whereas local recurrence and secondary enucleation were expected at least 10%
and 20% of the time after IBT, respectively, based on data for medium-sized
melanomas,57;73;212;220 and that neither treatment was expected to give any significant
advantage in preventing metastasis and improving survival as compared to the other.
Enucleation was recommended if the patient had a ring melanoma, a melanoma
larger than the largest brachytherapy plaque, an extrascleral tumor extension over 2 mm, a
tumor that grew around the optic disc or a tumor that was associated with a complication such
as suprachoroidal bleeding or extensive retinal detachment, vitreous hemorrhage or iris
neovascularization, which are associated with poor visual prognosis. Otherwise, the patients
were managed according to their personal preference after informed consent was obtained.
In Study IV, TSR was not performed on tumors larger than 16 mm in diameter, those
with retinal perforation, or on patients who were unfit for hypotensive anesthesia because of
e.g. uncontrolled hypertension, liver or renal disease, cerebrovascular disease or ischaemic
heart disease. TSR was usually not recommended if vision was already poor at diagnosis. The
main alternatives for managing large tumors were enucleation and proton beam therapy.
If a local recurrence developed, secondary enucleation was recommended and
patients who refused were managed with reirradiation. Also, if visibility to the fundus was
lost, the patient was offered secondary enucleation as a safety measure. Most patients in the
Finnish study populations elected to continue follow-up with ultrasonography, CT and MRI,
whereas secondary enucleation was more readily recommended and performed to the TSR
patients of Study IV.




5.3.1. Iodine Brachytherapy (I-IV)
Iodine-125 applicators were crafted in 1991 by a goldsmith to conform with the shape of
ruthenium-106 plaques already in use.131 Four 0.5 mm-thick unrimmed, non-collimating
plaques were used: CCB (diameter 20 mm, circular, 10 seeds), CCC (Fig.1A; 25 mm,
circular, 12 seeds), COB (20 mm, notch for the optic nerve, 9 seeds) and CIB (diameter 20
mm, notch for the limbus, 8 seeds). Seeds were attached with silicone rubber (RTV 3140;
Dow Corning, Midland, MI) that increased plaque thickness to 1.0-1.5 mm. The first
treatments of the series used either 10 mCi  or 15 mCi seeds (model 6702; Mediphysics,
Arlington Heights, IL) but since August 1994, 15 mCi was the standard seed intensity.
The dose to tumor apex was calculated at the time of the treatment with commercial
brachytherapy software (Cadplan, Varian Dosetek, Helsinki, Finland). The angular and
distance dependence dose rates were determined from tabulated correction matrices that
included absorption and scatter correlations.131;171;310 In 1995, the software was modified
according to American Association of Physicists in Medicine Radiation Therapy Committee
Task Group No.43.203
The prescription point was tumor height plus 1 mm for the sclera. Prescription dose
was initially 100 Gy, and 80 Gy if the tumor was very thick in an effort to limit
complications. Since 1997, the prescription dose has been 80 Gy to the apex, and very thick
tumors have received a prescription dose of 70 to 60 Gy. Treatment time was calculated from
the central axis depth dose curve. Seeds were replaced when the times approached two weeks.
Some treatments taking place just before receiving a fresh batch of seeds were carried out
loading the plaque with additional seeds from the old batch to shorten treatment time. Three
patients had treatment times in excess of 450 hours when delivery of seeds was delayed.
The tumor was localized with transillumination using a fiberoptic probe, indirect
ophthalmoscopy with scleral indentation, or both. A minimum safety margin of 2 mm around
the tumor was desirable, but not an absolute requirement. Tumors close to the optic disc and
macula were often irradiated with a smaller or no safety margin toward these structures.
Six patients received brachytherapy more than once. Three of these treatments were
planned continuation to, and took place within 12 weeks of, primary IBT, in order to cover an
exceptionally large or inconveniently shaped tumor. The remaining three brachytherapies
were secondary treatments warranted by local tumor recurrences. The former were delivered
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with two ruthenium-106 (CCB and CCC) and one iodine-125 plaque (CCB), whereas the
recurrences were treated with iodine plaques.
5.3.2. Local Transcleral Resection (IV)
The techniques used for transscleral local resection have evolved over time.63;70 The
resections were performed by the same surgeon (Damato) and under hypotensive anesthesia
to minimize hemorrhage. A partial-thickness scleral flap was prepared around the tumor,
which was resected together with the deep scleral lamella and a safety margin of surrounding
normal choroid, if possible. Adjunctive ruthenium-106 brachytherapy (RuBT; 100 Gy to 2-3
mm) was administered after surgery to 20 patients, all but one of them treated after 1995.
5.4. Data Collection
5.4.1 Baseline Evaluation (I-IV)
The diagnosis of uveal melanoma was based on clinical, ultrasonographic and, in selected
cases, fluorescein angiographic findings. The clinical parameters recorded at baseline
included tumor height and largest basal diameter (LBD), best corrected visual acuity (VA),
and intraocular pressure (IOP). Biomicroscopy using a +90.0 diopter convex lens (Volk
Optical Inc, Mentor, OH) and indirect ophthalmoscopy were performed to localize the tumor
margins, to evaluate its growth pattern, exudative retinal detachment and vitreous
hemorrhage, and to estimate distance from the posterior tumor margin to the optic disc and
foveola. Gonioscopy was used to determine the anterior border of the tumor and to detect
neovascularization of the iris, chamber angle, or both.
Liver function tests (AST, ALT, AP and LD), a chest radiogram and an abdominal
ultrasonography were obtained to detect metastases. In the case of amelanotic and otherwise
atypical tumors, mammography and whole body CT scans were ordered to exclude intraocular
metastasis and a primary malignancy elsewhere. One patient had metastases from uveal
melanoma at baseline and received IBT as a palliative treatment.
5.4.2. Clinical Follow-up
Patients were prospectively followed at 3, 6 and 12 months after brachytherapy and twice a
year thereafter for 3 years, and then at least once a year, often in a regional hospital. The TSR
patients were followed in a similar manner but reporting from the regional hospitals to the
study center was less routine in the UK than in Finland.
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Liver function tests, chest radiograph, and abdominal ultrasonography were
performed annually to screen for metastasis. In selected cases, they were also performed at 6
and 18 months after treatment. All follow-up data were prospectively collected into dedicated
computerized databases at both study centers.
5.4.3. Assessment of Local Tumor Control
Biomicroscopy, diascleral transillumination, indirect ophthalmoscopy, B-scan ultra-
sonography and, in selected cases, CT and MRI were used to assess tumor control.
Recurrence was coded as vertical, marginal, ring melanoma or extrascleral.128 An unequivocal
change of 1.0 mm or more in either dimension indicated local marginal or vertical recurrence,
respectively.
5.4.5. Assessment of Survival and Metastatic Status (I)
Survival status was classified as alive with or without metastasis, dead of metastatic
melanoma, other cancer and nonneoplastic causes, and unknown. Death certificates were
obtained from Statistics Finland and charts relating to terminal illness were retrieved. The
cause of death was coded as diagnostic of melanoma metastasis if histopathologic diagnosis
was confirmed in our laboratory by immunohistochemistry or, if the specimen was
unavailable, the original histopathology report documented unequivocal melanin. Otherwise
the cause of death was coded consistent with metastatic melanoma if based on histopathology.
Patients without histopathology who had evidence of metastasis and progressive course with
no evidence of a second cancer were considered to have suspected melanoma metastasis.296
Death due to other cancer necessitated histopathologic diagnosis. Death due to a
nonneoplastic cause was classified as certain only if an autopsy had been performed.
Otherwise it was required that the patient had no evidence of metastatic disease at the last
review, performed no more than six months before death.
5.4.6. Assessment of Visual Acuity (I-IV)
Visual acuity was measured using the Snellen chart using the patient’s own optical correction
or pinhole if the vision was reduced. VA worse than 20/400 was recorded as counting fingers,
hand movement, light perception and no light perception.
5.4.7. Assessment of Complications (II-IV)
Time to the following outcomes was assessed from a computerized tumor registry:
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1. Progression of lens opacity, typically initially posterior subcapsular cataract in
type, which decreased or would have decreased visual acuity if vision was reduced because of
other reasons, evaluated by slit lamp biomicroscopy.
2. Neovascularization of the iris, chamber angle or both, evaluated by slit lamp
biomicroscopy and, if suspicious vessels were seen or IOP was elevated, by gonioscopy.
3. Glaucoma, defined as IOP over 24 mmHg as measured by applanation tonometry
and either confirmed at the next follow-up examination or considered an indication for
treatment.
4. Maculopathy, categorized as scarring, macular pucker, cystic macular edema, or
radiation retinopathy (retinal hemorrhages, microaneurysms, microinfracts, edema or
exudation), evaluated by slit lamp biomicroscopy using a noncontact or contact lens.
5. Optic neuropathy, categorized as radiation papillopathy (edema, peripapillary
splinter hemorrhages or microinfarcts) or optic atrophy.
6. Vitreous hemorrhage occurring or recurring after IBT, evaluated by binocular
indirect ophthalmoscopy.
7. Retinal detachment (RD) involving at least one quadrant, which first occurred or
increased by one quadrant or more after IBT and persisted for more than 6 months, evaluated
by indirect ophthalmoscopy or by ultrasonography after visibility to the fundus was
compromised. Transient RD that resolved and localized RD directly over or around the tumor
was disregarded.
5.4.8. Assessment of Cosmesis (I-II)
Cosmetic outcome was classified as normal, minor abnormality (e.g. persistent redness,
inconspicuous scleral thinning, slightly asymmetric pupil, or cataract visible to the naked eye
without other cosmetic abnormality) and major abnormality (e.g. visible corneal opacity,
rubeosis, or hyphaema, phthisis bulbi, or presence of two or more minor abnormalities).
Redness due to recent surgery and similar temporary abnormalities not present at the next
examination were not counted.
5.4.9. Retrospective Analysis of Dose Distribution  (III)
All 96 treatments of the first study period were retrospectively modeled with a therapy
planning software, Bebig Plaque Simulator (BPS; version 4.12, Bebig GmbH, Berlin,
Germany) based on prospectively collected data in the registry of the Ocular Oncology
Service on the size, shape, and location of the tumor and the axial length (AL) of the eye at
Patients and Methods
47
the time of primary treatment. In 50 models, these data and the shape of the eye were obtained
from computed tomography and magnetic resonance images. Otherwise, the model was based
on clinical and ultrasonographic data in 25 models, and an average AL of 23.0 mm, modified
by 0.45 mm for each 1 D of refractive error in 21 models when the AL had not been recorded.
For tumors higher than the radius of the eye, the maximum height directly allowed by the
BPS, dose to the tumor apex was calculated at the corresponding depth along the tumor
central axis.
Each plaque and seed combination was created in the BPS. Templates provided for
the Bebig ruthenium plaques and a beta version (5.0.9B3) of the software was used to model
two secondary ruthenium treatments for optimal accuracy.9 The plaques in the model were
positioned by consensus of two investigators, based on location of the plaque,
transillumination shadow, extraocular muscles, and the limbus as recorded in the patient
charts. Typically, the surgeon recorded the distance of the tumor shadow and anterior plaque
margin from the limbus and the insertions and margins of adjacent extraocular muscles, and
the positions of the fixation holes of the plaque relative to extraocular muscles. In five
models, it was necessary to presume that the plaque had slid along the optic nerve, and offset
from scleral surface (wobble) was applied accordingly.
In practice, the positioning of the seeds in the plaque may have varied up to 1 mm
radially. It was estimated that the position of a round plaque on the scleral surface may have
deviated from the modeled position up to 2 mm radially and circumferentially. As a
sensitivity analysis, a subgroup of 20 eyes irradiated with the round CCB and CCC plaque
(which were used in 80 of the 96 treatments) was drawn at random, and doses to tumor apex
and the center of the lens, macula and optic disc were recalculated after a random
displacement of either the seeds or the plaque within these limits.
Dose distribution was modeled using linear source approximation, correction for
anisotropy, silicon carrier, and gold shell collimation. The following parameters were
recorded from the program output: dose and dose rate at tumor base (inner scleral surface) and
apex, at the center of the macula and the optic disc, at the posterior pole and center of the lens,
at the nearest and farthest point of the chamber angle, and, when applicable, at the retina
opposite to the plaque center. Ratios of tumor apex dose to tissue dose, including the
previously introduced T:M (tumor apex relative to the macula) and T:D (tumor apex relative
to the optic disc) ratios,11 were calculated.
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If a patient had undergone secondary brachytherapy within 3 months of the primary
treatment, the doses were added for analysis. If secondary brachytherapy was given later, the
patient was censored from analysis at that time.
5.4.10. Extrapolated Response Dose (III)
To take into account the biological effects of dose rate and tissue susceptibility, extrapolated
response doses (ERD) for each tissue were calculated from a linear-quadratic equation
appropriate for non-permanent implants with a decaying radiation source:62
ERD = D * (1+[(2R0λ)/(µ-λ)*( β/α)]) * [1-exp(-λT)]-1 *
( (1/2λ)*[1-exp(-2λT)] – (µ+λ)-1*[1-exp(-T(µ+λ))] )
where D is BPS dose, R0 is dose rate at the start of treatment, T is treatment time, λ is
radioactive decay constant (0.693/the half-life of the isotope), α/β is a tissue-specific ratio of
two constants representing cell damage and repair, and µ is a time constant (0.46 h-1). A small
α/β-ratio is typical of healthy, late reacting tissues capable of repairing radiation damage,
whereas a large α/β-ratio is typical of early reacting malignant tumors with limited repair
capability. An α/β-ratio of 9.75, based on an average α/β of various uveal melanoma cell
lines,300 was used for tumor tissue, 1.2 for the lens,233 and 2.5 was assumed for retina, optic
nerve and other late-reacting normal tissues. Patients who underwent secondary
brachytherapy were excluded from the analysis.
5.4.11. Simulation of Treatment with Collimating Plaques (III)
A collimating design for the round CCB and CCC plaques was created with the BPS. Notched
COB and CIB plaques were not redesigned because dose to the optic nerve would be high in
spite of collimation, and collimation at the limbus would have little effect on already low
doses to the fovea and optic disc. Furthermore, the margins of ciliary body tumors are difficult
to localize accurately and in both locations scattered radiation outside the plaque margins is
likely to improve local tumor control. Patients managed with two sequential plaques or who
received secondary brachytherapy were excluded from the analysis.
The CCB and CCC plaques were redesigned to have the same diameter, external
shape and number of seeds as the plaques used in the actual treatments, but to be 1.0 mm
thicker (Fig.3B). Along the plaque margin, 6 (CCB) or 8 (CCC) seeds were placed in 5.0 mm-
long and 1.1 mm-deep slots (offset, 0.6 mm) in the gold shell to obtain a collimating effect
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that reduces laterally directed radiation. The 4 seeds in the plaque center were not placed in
collimating slots in order to ascertain adequate radiation of the entire tumor base. They were,
however, arranged as a cross to take advantage of seed anisotropy in reducing radiation to
adjacent tissues (Fig.3).
The position of the plaque and the activity of the seeds were taken from the actual
IBT. If other than the default number of seeds had been used in the actual treatment (2 with
less, 5 with more than the default), the redesigned plaque was loaded with the default number,
adjusting the reference date to keep treatment time within two weeks. If the plaque had
apparently slid along the optic nerve, the redesigned plaque was moved to avoid the slide.
The end date of treatment was altered, if necessary, to deliver the following
prescription dose to the tumor apex: 80 Gy to tumors ≤12 mm or less in height, 70 Gy to
tumors >12 and ≤14 mm, and 60 Gy to tumors >14 mm. Dose to the macula and optic disc
were calculated with the BPS and compared with corresponding doses from the actual
treatment, based on both absolute doses and the T:M and T:D ratios, the latter of which are
not influenced by any change in the prescription dose.
Figure 3. Diagram showing
the concave surface with
seed placement and a two-
dimensional isodose plot
from the plaque simulator
software of A the 25-mm
CCC plaque used for iodine
brachytherapy in our center
and B a prototype
collimating CCC plaque
used in the simulation. Note
shift of the isodose curves
away from the posterior
pole in B. Inset, cross-




5.5. Statistical Methods and Data Analysis
5.5.1. General Guidelines
Follow-up data up to the date of analysis, November 30, 2001 for the studies I-III and May
30, 2004 for Study IV, were prospectively collected into dedicated databases in both study
centers.
The data were analyzed with Stata statistical software (Release 7.0, Stata Co.,
College Station, TX) with the -stcompet- automatic do-file (Boston College Statistical
Software Components Archive, available at http://ideas.repec.org/s/boc/bocode.html) and R
statistical software (version 1.4.0, The R Foundation for Statistical Computing, Vienna,
Austria; available at http://www.r-project.org) with the -cmprsk- library.
Descriptive statistics are given as the median and range and 95% confidence
intervals are calculated for key findings. Time-to-event data such as time to development of a
complication, local tumor recurrence, and metastatic disease were analyzed by two closely
related methods: Kaplan-Meier survival analysis and Cox proportional hazards regression in
Studies I and III and cumulative incidence analysis and competing risks regression in Studies
II and IV..
5.5.2. The Kaplan-Meier Method
The Kaplan-Meier product limit method is considered the standard in survival analysis. In a
setting with no competing risks, Kaplan-Meier provides the most accurate estimates of the
proportion of patients with the event of interest. The method, originally developed to assess
mortality,214 assigns each patient in the data set one of two possible outcomes, censored or
event. It also assumes that all patients censored from analysis are still at risk of the event of
interest.107 However, when analyzing an event other than death, a patient may be rendered
immune to the event of interest by one or more competing risk events and should therefore be
removed from the population at risk at that time107 (e.g. an eye cannot develop a cataract after
enucleation nor can a patient become blind after dying of metastatic melanoma). Using the
Kaplan-Meier method in a setting with frequent competing risks tends to overestimate the
proportion with the event analyzed. On the other hand, it also excludes the effect of
competing events from the analysis where they can be considered confounding factors as
regards the aims of the study.41;43 If the effect of competing risks is relevant for the aim of the
study, it is preferable to use cumulative incidence analysis instead.
Patients and Methods
51
5.5.3. Cumulative Incidence Analysis
Cumulative incidence analysis takes competing risks into account by considering a third
possible outcome in addition to censored and event: a competing risk event. A patient with a
competing risk event is censored from the analysis but not considered to be at risk of the event
of interest like those censored at the end of follow-up. This avoids overestimating the
remaining population at risk, and consequently, the incidence of the outcome.
For example, in the analysis of ocular complications (II), death and enucleation were
modeled as competing events, after the occurrence of which the patient was no longer at risk
of the event of interest.
5.5.4. Analysis of Survival (I)
Analyses of both all-cause and melanoma-related survival were based on the Kaplan-Meier
method.137 To address selection bias, the survival of all 121 patients who had large uveal
melanomas was also assessed.
5.5.5. Analysis of Local Tumor Recurrence, Eye Retention, Metastases and Cosmesis (I)
In the first study, Kaplan-Meier analysis was used to assess time to secondary enucleation and
time to development of local recurrence, metastases, and abnormal cosmetic appearance of
the tumor eye. In Study II, the same outcomes were assessed with cumulative incidence
analysis for comparison when this method became available. In Study IV, cumulative
incidence analysis was used to assess local tumor recurrence.
5.5.6. Analysis of Vision Loss (I-IV)
This key outcome was analyzed using several different approaches. The main endpoints were
development of unilateral low vision (VA 20/70 or worse) and unilateral blindness in the
study eye (VA less than 20/400) using the World Health Organization criteria (I,III,IV). In
Study I, these were assessed using the Kaplan-Meier method and in Studies III and IV with
cumulative incidence analysis.
In order to facilitate comparison with the COMS studies two additional approaches
were used. First, mean VA, after transformation to a logarithmic scale and stratified by factors
associated with poor vision outcomes, was plotted at 6-month intervals (I,IV).189
Measurements below 20/1600, such as counting fingers or hand movement, were set equal to
20/1600. Enucleated eyes and eyes with no light perception were counted as having 20/2500
vision.189 If the patient did not have a measurement available at all appropriate intervals, the
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VA was taken to be the average of the previous and the next visits.189 If there was a longer
gap in follow-up, the patient was censored from the analysis. The second approach analyzed
time to loss of VA 20/40, 20/70 and 20/200, and loss of more than six lines of vision,
corresponding to quadrupling of the minimal angle of resolution from the baseline, using the
Kaplan-Meier method in accordance with the COMS Medium Tumor Study. Loss of vision
was recorded only when confirmed at the next follow-up examination.189
Person-years of vision conserved in the study eye was estimated by counting the total
time at risk for the COMS and WHO adverse visual outcomes, allowing for recovery and
repeated loss of vision with the multiple-failures per subject analysis (I). In Study IV
cumulative frequency of VA levels at baseline and at 1, 2, and 3 years after diagnosis was also
plotted, and compared using the Kruskal-Wallis test.
5.5.7. Analysis of Complications (II-IV)
Cumulative incidence instead of Kaplan-Meier analysis was chosen to analyze time to
individual complications in Studies II and IV, because the aim was to provide realistic
estimates of incidence for clinicians for counseling and deciding on appropriate therapy for
patients with a large uveal melanoma, a setting with frequent competing risks, particularly
metastatic death.
Kaplan-Meier analysis, which censors patients from the analysis when competing
risk events take place, provides unbiased estimates of the probability of complications in
patients who do not encounter any competing risk events.43 Because the aim of Study III was
to analyze late complications in order to reduce them, if possible, in surviving patients treated
in the future, and to isolate the effect of dose-related variables, the Kaplan-Meier method was
chosen to factor out the effect of competing risks. Kaplan-Meier survival curves were used to
summarize time to complications of interest for descriptive purposes in Study III. To visually
assess threshold doses and dose ratios, the curves were superimposed with a scatterplot
depicting the dose received by an individual patient and the reason for censoring the patient
from analysis, if applicable.
To assess the prevalence of potentially reversible complications (cataract, abnormal
IOP, vitreous hemorrhage, and RD), the proportion of patients with the complication was
calculated at each time point. Patients with missing data were considered to have a
complication if it was present at the previous and a subsequent visit no more than 6 months
later. A patient with longer data gaps and those with a missing IOP measurement were
censored from the calculation at that time point.
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5.5.8. Number Needed to Treat (I,IV)
The number of patients needed to treat with IBT instead of enucleation for one additional
patient to benefit (NNTB) by maintaining 20/400 vision or better in the tumor eye for at least
2 years from treatment was calculated with its 95% confidence interval using the Wilson
score method.5;30
The number of patients needed to treat with TSR instead of IBT to achieve the same
benefit was assessed in Study IV. This method was also used to estimate the harm from local
tumor recurrence were the patients managed with TSR instead of IBT. A negative number
needed to treat indicates that one additional patient will be harmed (NNTH) by the treatment
for the specified number of patients treated.
5.5.9. Proportional Hazards Regression
Proportional hazards regression models were used to assess individual baseline tumor and
host-related risk factors associated with time to vision loss and time to each complication after
treatment. In Studies I and III employing the Kaplan-Meier method, Cox proportional hazards
regression models were used. Cumulative incidence analysis with competing risks regression
(CRR) models were used to assess complications in Studies II and IV. Factors predicting
vision loss were modeled in Studies I and III with Cox proportional hazards regression, based
on both single-failure (time to first event) and multiple-failure (repeated events) data sets.56;297
Because competing risks regression, as currently implemented in available software, can not
be used to appropriately analyze counting process type data, multiple-failure models for
vision loss could not be used in Study IV.
In Studies I and II associations between individual risk factors and events of interest
were first studied at univariate level. Age at diagnosis, LBD, tumor height and the distance of
posterior tumor margin to FAZ were modeled as continuous variables. Location of the
anterior tumor margin was dichotomized (behind the ora serrata, in the ciliary body).
Variables were selected to multivariate models from those explanatory variables that were
significantly associated (P<0.10) with the event of interest by univariate analysis, and from
generally known potential confounders (e.g. increasing age predisposes to cataract).
Confounding variables were kept in the model irrespective of statistical significance.124 In
Study III, dose-related variables that were significant at univariate level were entered into
models based on previous studies to assess whether they better explain the recorded events. In
Study IV, the effect of treatment type (TSR vs. IBT) on complications was assessed using
competing risks regression models based on best-fitting models from Study II.
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The number of variables in the final model was restricted, based on a rule to have at
least 15 to 20 events per each additional variable.214 The assumption of proportional hazards
was tested by the method of Therneau and Grambsch,297 which utilizes scaled adjustment of
Schoenfeld residuals, allowing interpretation of the smoothed residuals as a nonparametric
estimate of the log hazard ratio function, both globally and for individual covariates in the
model. The regression coefficients and hazard ratios (HR) with 95% confidence intervals
were calculated. Standard errors were calculated using the robust variance estimator of Lin
and Wei,170 and tied survival times were handled with Efron approximation.137 Models were
compared using the deviance test.137
5.5.10. Logistic Regression (IV)
In Study IV, an exploratory Cox proportional hazards regression model for VA loss did not
fulfill the assumption of proportional hazards.297 Instead, logistic regression models which
included treatment type and patient age, tumor height-to-diameter (H:D) ratio and baseline
VA as confounders, were used to analyze VA loss at 1, 2, and 3 years from treatment.
5.5.11. Analysis of Agreement and Uncertainty in Dose Calculation (III)
Agreement in dose calculation between the original treatment planning and BPS was assessed
by plotting the difference between the measurements against their mean, and by calculating
the mean difference.4 Uncertainty in the BPS doses to adjacent tissues, based on the
sensitivity analysis, was estimated with the same method.
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6. Results and Discussion
6.1. Iodine Brachytherapy for Large Uveal Melanomas – Results,
Complications and the Effect of Dose Distribution (I-III)
6.1.1. Baseline Population Characteristics
The median age at diagnosis of the 97 patients (male:female, 49:48), all Caucasian, managed
with IBT was 64 years (range, 24-82). The median follow-up time was 3.5 years (range, 0.3-
10.4). Only three patients had 20/20 vision at diagnosis, whereas 29 (30%) had an acuity of
20/200 or worse (Table 1 in I). According to the WHO definitions, 35 (36%) study eyes had
low vision and 19 (19%) were blind.
6.1.2. Baseline Tumor Characteristics
The median tumor height and LBD were 10.7 mm (range, 4.5-16.8) and 16.1 mm (range, 7.3-
25.0), respectively (Fig.4A). Of the 97 tumors, 10 (10%) were classified large based on their
peripapillary location,57 and 61 (63%) involved the ciliary body. The posterior margin of the
tumor touched the optic disc in 15 (15%) eyes and extended to within 2 mm of it in 8 (8%)
eyes (Fig.4C). The median distance to the center of the foveal avascular zone (FAZ) was 6.0
mm (range, 0-18).
As compared to the COMS Large Tumor Study (Table 1 in I)57, the tumor height was
skewed toward higher values (mean, 10.8 vs. 9.5 mm; P < 0.001 Kruskal-Wallis test), and the
LBD toward smaller values (mean, 16.2 vs. 17.2 mm; P = 0.001 Kruskal-Wallis test).
6.1.3. Dose Distribution and Dose Rate
The tumor apex (prescription point) was a median of 11.3 mm from the outer scleral surface.
The median prescribed dose was 87 Gy (range, 42-109) at a median dose rate of 57 cGy/h
(range, 13-217, Fig.5A). Median treatment duration was 147 hours (range, 42-599).
The median BPS dose at tumor apex and tumor base was 81 Gy and 384 Gy (Fig.6).
The median dose rates at these points were 53 cGy/h (range, 11-204) and 289 cGy/h (range,
84-1213), respectively. The range of dose rates at tumor apex was considerably wider than the
ones stated in the COMS protocol and the American Brachytherapy Society (ABS)
recommendations (Fig.5A). The median BPS doses to the center of the macula and optic disc
were 79 Gy and 83 Gy (Fig.6). The median T:M ratio was 1.03 (range, 0.12-6.65), and the
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Figure 4.  Size and location of the uveal melanomas in the present study. A, Scatter plot of largest tumor basal
diameter against tumor height of the 121 large tumors of which 96 were managed with primary iodine
brachytherapy (IBT). Circles indicate tumors managed with IBT. Tumors closer than 2 mm from the optic disc
were considered peripapillary. The dashed lines indicate the COMS criteria for a large tumor. B, Similar plot of
the 87 tumors that were large because of tumor height and were managed by either IBT or transcleral local
resection (TSR) and enrolled in the fourth part of the study. C and D,  Plot of tumor location in studies I-III and
IV, respectively. Bars indicate the position of the anterior and posterior margin of each tumor.






















































































Figure 5. Scatterplot of dose to tumor apex against corresponding dose rate for 96 patients with a large uveal
melanoma who underwent iodine brachytherapy (A). Vertical bars show Collaborate Ocular Melanoma Study
(COMS) and American Brachytherapy Society (ABS) guidelines for dose rate, and solid dots indicate primary
treatment with two sequential plaques. (B) Scatterplot of agreement between originally calculated dose to tumor




The mean difference between the prescription and BPS dose at tumor apex was -2.8
Gy (range, 59 Gy decrease to 30 Gy increase, Fig.5B).  In 78 (81%) eyes, the BPS dose was
within ±10 Gy of the prescribed dose. Differences greater than 10 Gy were most likely the
result of probable sliding of the plaque along the optic nerve (5 eyes), misjudgment of tumor
height because of oblique B-scans in some early treatments (8 eyes), and overestimation of
total dose to tumor apex from two partly overlapping subsequently applied plaques (2 eyes).
Sensitivity analysis indicated mean differences in BPS dose to the macula and the
optic disc due to random error in plaque positioning were -5 Gy and -4 Gy (Fig.2C in III),
respectively, and mean differences due to random seed displacement were -2 Gy and +0.4 Gy
(Fig.2D in III), respectively. Differences of more than ±20 Gy in BPS dose to the macula and
optic disc were rare, but occurred when the plaque was within 1 mm of these structures and
the BPS dose was consequently high (Fig.2C,D in III).
The accuracy of the Bebig Plaque Simulator has been evaluated by others,162;209 and
it has proven to be a reliable tool for brachytherapy planning. In most of the retrospective
cases modeled in the present study, the simulated dose matched the prescribed dose very
closely and, given the three-dimensional detail of the BPS treatment plan, the former is likely
to be a closer estimate of the dose actually delivered. This is especially true in cases where the
simulation showed that, provided that the AL and/or MRI measurements of the eye size and
the location of the sutures documented in the surgery report were accurate, the plaque must
Figure 6. Diagram showing mean
dose, median dose and dose range in
Grays to specific points of the tumor
and the eye as calculated with the
plaque simulator software for 96
patients with large uveal melanomas
who underwent iodine brachytherapy.
Numbers in parentheses indicate the
mean, median and range of the ratios
of the corresponding dose relative to
the dose at tumor apex.
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have tilted along the optic nerve sheath during placement. With therapy planning software
such as the BPS, which considers the individual anatomy of the tumor eye, such difficulties
can be predicted in the planning phase and miscalculations of the dose distribution limited.
6.1.4. Survival
Of the 97 patients, 34 died during the follow-up and 28 of these deaths were classified as
being due to metastatic uveal melanoma. Of the 28 melanoma deaths, 19 (68%) were
histopathologically confirmed (17 were diagnostic of and two consistent with metastatic
melanoma), and nine were suspected on the basis of clinical data. Additional eight patients
were alive a median of 14 months (range, 2-32) after diagnosis of metastases. One patient was
dead of histopathologically confirmed metastatic carcinoma of the colon and five patients
died without evidence of melanoma metastases (three of myocardial infarction and two of
cerebrovascular accident).
The Kaplan-Meier estimate for all-cause survival was 62% at 5 years (95% CI, 49-
72%) and 48% at 8 years (95% CI 33-61%; Fig.7A) The estimated melanoma-specific
survival was 65% (95% CI, 52-75%) and 54% (95% CI, 38-68%) at 5 and 8 years
respectively (Fig.7B). These survival curves are visually comparable to the melanoma-
specific survival after enucleation in the COMS Large Tumor Study (based on the originally
published graph,294 which corresponded to melanoma-specific mortality defined as death with
histopathologically confirmed metastasis or, if histopathology was not available to confirm
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Figure 7.  A, Kaplan-Meier plot of all-cause survival for 97 patients with uveal melanoma large by
Collaborative Ocular Melanoma Study (COMS) criteria who were managed with iodine brachytherapy
(IBT). Survival for the entire series of 121 patients with large uveal melanomas, and for patients who
underwent enucleation without prior irradiation in the COMS Large Tumor Study are shown for comparison.




the source of metastasis, with suspected melanoma metastasis; Diener-West M, personal
communication, 2002). This is in spite of the fact that, unlike COMS, the present study did
not exclude patients who had a history of major illness, other cancer or metastases at
diagnosis. Using cumulative incidence to allow for competing causes of death, melanoma-
specific survival was 66% (95% CI, 55-77%) at 5 years and 57% (95% CI, 44-71%) at 8
years.
The results are also in line with those from other studies of predominantly large
uveal melanomas.237;246 In can be argued, however, that the median follow-up of 3.5 years of
the present study was insufficient to reveal a possible late increase in mortality caused by
post-treatment metastasis spawned by viable tumor cells. Based on tumor doubling times it
has been estimated that a follow-up less than 8 years may not detect this late increase in
mortality.180 However, no such late increase in mortality has been noted in any studies on eye-
conserving management of uveal melanoma with longer follow-up.20;24;51;108 This issue should
nevertheless be revisited when long-term follow-up data after IBT becomes available.
6.1.5. Tumor Regression and Local Tumor Recurrence
After IBT, tumor height regressed a median of 38% (range, 85% [14.3 mm] decrease to 5%
[0.5 mm] increase) by 1 year and 48% (range, 82% [10.7 mm] decrease to 4% [0.4 mm]
increase) by 3 years. By 1 and 3 years, 30% and 23% of tumors had regressed by less than one
third, and 14% and 23% had regressed by two thirds or more in height, respectively.
Local tumor recurrence was diagnosed in 5 patients, all within 3 years from
treatment. Two were classified as extrascleral marginal (perilimbal at tumor margin), two as
vertical and one as a ring melanoma. Two were controlled with additional IBT (one later
developed an extrascleral marginal recurrence) and three were managed with secondary
enucleation. The Kaplan-Meier estimate for developing first local recurrence was 6% (95%
CI, 2-14%) by 5 years (I). The 5-year cumulative incidence of local tumor recurrence was also
6% (95% CI, 2-12%; Fig.8A), lower than those of the competing risks, secondary enucleation
(11%) and death (44%). The small number of locally recurring tumors in this data set
precluded a regression analysis of baseline risk factors for recurrence.
The 5-year 6% recurrence rate compares favorably with the 10.3% risk of treatment
failure at 5 years143 reported by the COMS Medium Tumor Study and with several
observational series with mainly medium-sized tumors, in which the 5-year Kaplan-Meier
estimate for developing local tumor recurrence after IBT has ranged from 8% to 20%.219;220;267
This is irrespective of the fact that, if indicated to reduce radiation to the optic disc and
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macula or to cover a very large tumor, an absolute 2 mm safety margin around the tumor was
not required in the present study. The plaques used differed from the COMS plaques in that
they do not have a collimating rim, and coverage of the tumor with a smaller safety margin
was considered sufficient because of lateral scatter of radiation.11 A prescription dose lower
than the 85 Gy required by COMS was used to treat very thick tumors, and the dose rate was
allowed to vary more widely.76
The possibility that some recurrences may have been missed must be considered,
because in several eyes treatment-related complications eventually prevented view to the
fundus. Secondary enucleation was offered when visibility was lost, but most patients
declined further therapy in the absence of evidence of recurrence unless the eye was irritated
and enucleation promised symptomatic relief. So far, no delayed recurrences have been
observed, although these patients are closely reviewed both by standard and high-frequency
ultrasonography and by periodic CT and MRI, and the longest follow-up times exceed 13
years. Furthermore, considering that the risk of dying of metastatic melanoma by cumulative
incidence analysis was more than seven times higher that that of recurrence at 5 years, it is
also possible that some large tumors, which would have recurred locally after IBT, caused
metastatic death before a local recurrence was observed.
The data suggest that large tumor size does not predict more frequent local
recurrence after IBT as compared to medium-sized tumors.219;220;267 This conclusion, also,
should be revisited when follow-up data accumulates. Local recurrence has been associated
with high risk of metastasis,81;128;305 but it is not known whether this is because tumor cells
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Figure 8. Cumulative incidence of A, local tumor recurrence; B, cosmetic abnormality of the tumor eye after
iodine brachytherapy of a large uveal melanoma. Cumulative incidence of secondary enucleation and death,




disseminate from the recurring tumor or because of greater inherent malignancy of tumors
that recur.53  Finding the answer merits further research, since it would not only greatly
influence the treatment conventions but also increase our understanding of the metastatic
process.
6.1.6. Eye Retention and Cosmetic Outcome
In addition to the three eyes removed after recurrences, one primary enucleation instead of
IBT was performed when extraocular extension was detected at surgery, and eight eyes were
removed a median of 12.5 months (range, 0.3-58) after diagnosis because of complications,
mostly uncontrollable neovascular glaucoma. The Kaplan-Meier estimate for conservation of
the eye was 84% (95% CI, 72-92%) at 5 years (Fig.2E in I).
It is important to note, that eye retention rate as a measure of success of the primary
treatment is confounded by the indications for secondary enucleation of the study center,
which makes direct comparison between reports misleading. The present study represents a
rather conservative approach to enucleation. This is a result of both the clinical conventions of
the study center and the reluctance of many patients to undergo enucleation, sometimes even
when usable visual acuity and fundus visibility were lost and enucleation was recommended
as a safety measure.
Of the retained eyes, 41 had normal cosmesis at last follow-up. The 5-year
cumulative incidence of any cosmetic abnormality was 30% (95% CI, 20-41%; Fig.8B). The
risk of developing complications which result in symptoms and discomfort in the tumor eye is
probably one major reason why enucleation has been recommended as primary therapy for
large uveal melanoma. This used to be the practice at this study center, too, but experience has
proven that, given the option, most of our patients elect IBT in spite of these unfavorable
odds. Ocular oncologists in general pay more and more attention to the patient’s own
objectives when discussing treatment.64;68
6.1.7. Preservation of Visual Acuity
Among the 96 patients, five avoided low vision for at least 2 years. The cumulative
incidence of low vision was 76% (95% CI 61-85%) at 1 year, 85% (95% CI, 71-93%) at 2
years, and 93% (95% CI, 80-98%) at 3 years (Fig.9A).
Sixteen patients avoided blindness for at least 2 years. The cumulative incidence of
blindness was 47% (95% CI, 35-57%) at 1 year, 69% (95% CI, 57-78%) at 2 years, and 84%
(95% CI, 73-91%) at 5 years (Fig.9B).
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A total of  49 person-years without low vision (median, 0.6 years per patient who
initially had this level; range, 0.04-8.2) and 111 person-years without blindness (median, 1.0
year; range, 0.03-8.6) of the study eyes were saved by IBT compared to enucleation.
6.1.7.1. Clinical Factors Predicting Visual Loss
By univariate, single-failure Cox regression analysis, tumor height was a significant risk
factor for developing low vision and blindness in the study eye (hazard ratio [HR] 1.38 and
1.31 for each mm increase, P = 0.001). Age at diagnosis was also a significant risk factor for
low vision (I). By multiple-failure analysis, which allows repeated loss and recovery of vision
(I), location of the anterior tumor margin behind the ora serrata became a significant predictor
of blindness (HR 1.68, P = 0.011) and distance of the posterior tumor margin from FAZ a
predictor of both low vision and blindness (HR 0.94 for each mm increase, P = 0.009 and
0.010, respectively) in the study eye. LBD was not significantly associated with visual loss in
any analysis.
Bivariate regression identified tumor height on one hand, and location of the anterior
tumor margin behind the ora serrata and short distance from posterior tumor margin to the
FAZ on the other hand, as independent predictors of both low vision and blindness in the
study eye. The model which combined height with location of the anterior tumor margin
better predicted development of low vision in the study eye by single-failure analysis than the
alternative model, which included distance to FAZ, and the two models were comparable by
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Figure 9. Cumulative incidence of A, first loss of 20/70 and B, first loss of 20/400 visual acuity (VA) level,
corresponding to the World Health Organization’s definitions of low vision and blindness, respectively, after
iodine brachytherapy of a large uveal melanoma. Cumulative incidence of secondary enucleation and death,




Table 3. Cox proportional hazards regression of time to low vision (20/70 or worse) and blindness (loss of 20/400) in the study eye, based on single and multiple failure data sets
Single failure Repeated failure
Coefficient Wald Hazard ratio Coefficient Wald Hazard ratio
Variable (SE) chi-square P (95% CI) (SE) chi-square P (95% CI)
BIVARIATE ANALYSIS
Low Vision -2 Log Likelihood = 214.05 -2 Log Likelihood = 351.18
Tumor height†  0.427 (0.101) 17.8 <0.001 1.53 (1.26-1.87)  0.310 (0.066) 22.0 <0.001 1.36 (1.20-1.55)
Anterior tumor margin‡  1.237 (0.408)   9.18 0.002 3.45 (1.55-7.67)  0.672 (0.206) 10.0 0.001 1.96 (1.31-2.93)
Blindness -2 Log Likelihood = 418.67 -2 Log Likelihood = 614.12
Tumor height†  0.333 (0.089) 14.1 <0.001 1.39 (1.17-1.66)  0.266 (0.065) 16.6 <0.001 1.30 (1.15-1.48)
Anterior tumor margin‡  0.689 (0.285)   5.86 0.016 1.99 (1.14-3.48)  0.796 (0.210) 14.3 <0.001 2.22 (1.47-3.35)
TRIVARIATE ANALYSIS
Blindness -2 Log Likelihood = 410.62 -2 Log Likelihood = 604.86
Tumor height†  0.338 (0.091) 13.9 <0.001 1.40 (1.17-1.68)   0.253 (0.062) 16.6 <0.001 1.29 (1.14-1.45)
Anterior tumor margin‡  0.763 (0.337)   5.11 0.024 2.14 (1.11-4.15)   0.670 (0.243)   7.62 0.006 1.95 (1.21-3.14)
Distance to FAZ†  0.014 (0.034)   0.17 0.68 1.01 (0.95-1.08)  -0.027 (0.027)   1.04 0.31 0.97 (0.92-1.03)
SE = Standard error, CI = Confidence interval, FAZ = Foveal avascular zone




multiple-failure analysis. They were also comparable in predicting development of blindness,
but in a trivariate model location of the anterior tumor margin became the predominant
predictor of blindness as well, together with tumor height (Table 3).
Although the long-term prognosis of preserving vision in an irradiated eye is poor for
most patients with a large uveal melanoma, even short-term conservation of vision in the
tumor eye appears to be preferable to many patients as compared to immediate blindness from
enucleation. Furthermore, because some patients maintain usable vision after IBT of a large
uveal melanoma, identifying the risk factors for VA loss can help in refining the treatment
protocol in order to extend this benefit to more patients.
6.1.7.2. Association Between Dose and Vision Loss
By univariate Cox regression, low vision and blindness of the tumor eye were associated with
dose to the optic disc (HR 1.04 and 1.06 for each 10 Gy increase, P=0.035 and P=0.001,
respectively, Table 2 in III) and macula (HR 1.06 and 1.10 for each 10 Gy increase, P=0.025
and P<0.001, respectively). In bivariate models with tumor height, dose to the macula
independently predicted low vision and blindness whereas dose to the optic disc
independently predicted only blindness (Table 2 in III).
Dose to the macula lost association with low vision in a trivariate model with tumor
height and location of the anterior tumor margin in the ciliary body (Table 2 in III), another
factor associated with vision loss in this data set. This model did not provide a better fit than
the corresponding bivariate model without ciliary body involvement. Dose to the macula
remained associated with blindness in a similar trivariate model, but this model did not
improve fit (P=0.10). Tumor height retained an independent association with loss of vision in
all models. Dose to the optic disc showed a weaker association with low vision than dose to
the macula, and provided a poorer fit as regards blindness (Table 2 in III).
The fact that loss of visual acuity was strongly related to the dose to the macula and
optic disc suggests that visual prognosis for these patients could be improved through a more
favorable dose distribution. However, tumor height, which correlates to the dose to adjacent
tissues and to tumor volume, remained independently associated with loss of vision even
when adjusted for dose to the macula and optic disc. This is an interesting finding, since
tumor height can also act as a surrogate variable for dose to key ocular tissues in
brachytherapy. This finding may reflect other adverse effects caused by the presence of a
large tumor, which are independent of radiation. It also indicates that, for clinical purposes,
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tumor height remains a robust predictor of high risk of major complications and vision loss
after IBT of a large choroidal and ciliary body melanoma.
6.1.7.3. Number Needed to Treat
The Number Needed to Treat (NNT) was 14 patients to allow one patient to retain 20/70
vision or better in the treated eye for at least 2 years, and the NNT was 6 to avoid blindness of
the treated eye in one patient for at least 2 years. It is impossible to predict which patients will
enjoy such a benefit after IBT, but both stratification by potential prognostic factors and Cox
multiple regression analysis suggested that location of the anterior tumor margin in the ciliary
body in addition to decreasing tumor height was the factor most consistently associated with
smaller risk of both low vision and blindness in the treated eye. Furthermore, because uveal
melanomas with ciliary body involvement are also associated with shorter survival,168 the
benefit from enucleation as regards avoiding potential treatment-related complications is
smallest for these patients who are at a greater risk of developing metastases early and dying
soon after diagnosis.
6.1.8. Complications and Their Management
6.1.8.1. Kaplan-Meier vs. Cumulative Incidence in Reporting Complications
Ocular complications were frequent after IBT of a large uveal melanoma. Expectedly, death
of metastatic melanoma was an important confounder. The cumulative incidence estimates of
various complications developing were a median of 6 percentage points lower than estimates
based on standard Kaplan-Meier analysis (Table 4). It seems reasonable to use cumulative
incidence analysis for reporting results of conservative treatment of eye cancer to avoid
exaggerating the frequency of the side effects. Until an effective treatment for disseminated
disease is found, a substantial number of patients with a large melanoma will succumb before
complications from treatment develop. Because of this, Kaplan-Meier analysis will provide
patients with an overly pessimistic estimate to consider when deciding whether or not to
choose IBT instead of enucleation.
6.1.8.2. Cataract
Cataract progressed in 65 patients, including those who received the lowest doses to the lens
(Fig.10A). By cumulative incidence analysis, cataract developed or progressed in 79% (95%
CI, 68%-86%) of the 89 phakic eyes within 5 years of IBT.
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By competing risks regression, tumor height (P=0.017) was associated with time to
cataract progression. In a trivariate model (Table 5), which took into account age and diabetes
(HR 1.78) as confounders, tumor height increased in significance. In a univariate Cox
regression model which included simulated dose, time to cataract progression was associated
with dose to the center (HR 1.15 for each 10 Gy increase, P=0.002) and posterior pole (HR
1.14 for each 10 Gy increase, P=0.003) of the lens. A trivariate model, which combined dose
to the lens center with age at diagnosis and diabetes as confounders (Table 6) did not improve
fit over the model based on the same confounders and tumor height (-2 Log likelihood 472.83
vs. 472.40, P=0.56, chi-square test, 1 df).
Of the 65 patients whose cataract progressed after IBT, 27 (42%) underwent cataract
surgery without complications, and 25 of these received an intraocular lens. Five years after
treatment, 43% (95% CI, 25-63%) of survivors had clinically significant lens opacity in the
treated eye and 57% (95% CI, 37-75%) had undergone cataract extraction either before or
after IBT (Fig.2A in II).
It seems, that with a large uveal melanoma it is difficult to avoid secondary cataract.
Fortunately, reports suggest that cataract extraction from an eye with a treated uveal
melanoma is a safe procedure,110;220;306 which was also the case in the present data set.
Table 4. Comparison between cumulative incidence and Kaplan-Meier estimates of the 5-year incidence of 
complications after iodine-125 brachytherapy of 96 patients with a uveal melanoma large by the 
Collaborative Ocular Melanoma Study criteria 
 
 Proportion with Event  





Cataract 79 % 85 % 6 (8 %) 
Iris neovascularization 62 % 68 % 6 (10 %) 
Glaucoma 60 % 66 % 6 (10 %) 
Maculopathy 52 % 59 % 7 (13 %) 
Optic neuropathy 46 % 53 % 7 (15 %) 
Vitreous hemorrhage 36 % 39 % 3 (8 %) 
Retinal detachment 25 % 27 % 2 (8 %) 
Recurrence 6 % 6 % <1 (9 %) 
Cosmetic abnormality 30 % 37 % 7 (21 %) 
Loss of 20/60 acuity 95 % 97 % 2 (2 %) 
Loss of 20/200 acuity 85 % 94 % 9 (11 %) 
‡ percentage points (% higher than the cumulative incidence estimate) 
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Figure 10. Cumulative incidence of A, development or progression of cataract; B, iris neovascularization;
C, glaucoma; D, maculopathy; E, optic neuropathy; and F, occurrence or recurrence of vitreous
hemorrhage after iodine brachytherapy of a large uveal melanoma. Cumulative incidence of secondary
enucleation and death, the main competing risks, are also plotted. Bars indicate 95% confidence intervals
and ticks show censored observations.
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6.1.8.3. Iris Neovascularization and Glaucoma
The cumulative incidence of iris neovascularization was 62% (95% CI, 50%-71%) at 5 years
(Fig.10B). In Cox proportional hazards regression modeling with simulated dose distribution,
iris neovascularization was associated with dose to the opposite retina in the 87 eyes for
which this variable was applicable (HR 1.72 for each 10 Gy increase, P=0.018), but
unassociated with dose to chamber angle and dose rate at all points measured. In trivariate
models, dose to the opposite retina (Table 6) and tumor height provided a similar fit.
Table 5. Competing risks regression of time to complication after iodine-125 brachytherapy of 96 patients
with a uveal melanoma large by the Collaborative Ocular Melanoma Study criteria
Coefficient Wald Hazard ratio
Variable (SE) chi-square P (95% CI)
Cataract
Tumor height*  0.204 (0.073)  7.75 0.005 1.23 (1.06 - 1.42)
Age† -0.015 (0.010) 1.00 0.15 0.99 (1.01 - 0.96)
Diabetes‡  0.578 (0.624) 1.00 0.35 1.78 (0.57 - 5.54)
Iris neovascularization
Tumor height* 0.147 (0.087) 2.89 0.089 1.16 (0.98 - 1.37)
RD at diagnosis‡ 0.557 (0.372) 2.23 0.14 1.74 (0.84 - 3.62)
Diabetes‡ 0.558 (0.762) 0.54 0.46 1.75 (0.39 - 7.78)
Glaucoma
RD at diagnosis‡ 0.776 (0.413) 3.52 0.061 2.17 (0.97 - 4.88)
IOP at diagnosis¶ 0.081 (0.041) 3.92 0.048 1.08 (1.00 - 1.17)
Maculopathy  (tumors located ≥2 mm from fovea)
Distance to fovea* -0.133 (0.055) 5.88 0.015 0.88 (0.79 - 0.97)
Age† -0.021 (0.018) 1.33 0.25 0.98 (0.95 - 1.01)
Optic neuropathy
Distance to disc* -0.1041 (0.055) 3.57 0.059 0.90 (0.81 - 1.00)
Diabetes‡ 0.6075 (1.103) 0.30 0.58 1.84 (0.21 - 15.95)
Vitreous hemorrhage
VH at diagnosis‡ 0.975 (0.531) 3.38 0.066 2.65 (0.94 - 7.51)
Tumor LBD* 0.067 (0.060) 1.23 0.27 1.07 (0.95 - 1.20)
Persistent retinal detachment
Tumor height*  0.268 (0.127) 4.46 0.035 1.31 (1.02 - 1.68)
Ciliary body involvement‡ -0.339 (0.491) 0.48 0.49 0.71 (0.27 - 1.87)
SE = Standard error, CI = Confidence interval, RD = Retinal detachment, IOP = Intraocular pressure,
VH = Vitreous hemorrhage, LBD = Largest basal diameter
* continuous variable, mm
† continuous variable, years
‡ coding no=0, yes=1
¶  continuous variable, mmHg
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The IOP was over 24 mmHg in 6 (6%) tumor eyes at diagnosis. Cumulative incidence
of glaucoma developing after IBT was 60% (95% CI, 48%-70%) at 5 years (Fig.10C). Of 51
glaucomas, 43 (84%) were neovascular, 5 (10%) secondary angle-closure, and 3 secondary
open-angle (possibly from scarring of the nearby chamber angle after IBT) in type. Of the 54
patients with iris neovascularization, 39 (72%) developed neovascular glaucoma. The
prevalence of IOP over 24 mmHg was 39% (95% CI, 20%-59%) at 5 years after IBT, and it
remained fairly constant between 2 and 6 years from treatment (Fig.2B in II).
Table 6. Cox proportional hazards regression of time to complication after iodine-125 brachytherapy of 96
patients with a uveal melanoma large by the Collaborative Ocular Melanoma Study criteria
Coefficient Wald P Hazard ratio
Variable (SE) chi-square (95% CI)
Cataract
Dose to lens center* 0.138 (0.044) 9.67 0.002 1.15 (1.05 - 1.25)
Age† 0.006 (0.011) 0.29 0.59 1.01 (0.98 - 1.03)
Diabetes‡ 0.134 (0.600) 0.05 0.82 1.14 (0.35 - 3.71)
Iris neovascularization
Dose to opp. retina* 0.056 (0.023) 5.81 0.016 1.76 (1.11 - 2.77)
RD at diagnosis ‡ 0.447 (0.420) 1.12 0.29 1.56 (0.69 - 3.56)
Diabetes‡ 0.718 (0.759) 0.90 0.34 2.05 (0.46 - 9.08)
Glaucoma
Dose to opp. retina*   0.736 (0.325) 5.11 0.024 2.09 (1.10 - 3.95)
Tumor height§ -0.038 (0.110) 0.12 0.73 0.96 (0.78 - 1.19)
IOP at diagnosis||  0.070 (0.047) 2.19 0.14 1.07 (0.98 - 1.18)
Maculopathy  (tumors located ≥2 mm from fovea)
Dose to fovea* -0.008 (0.007) 1.21 0.27 0.99 (0.98 - 1.01)
Distance to fovea§ -0.178 (0.073) 5.90 0.02 0.84 (0.73 - 0.97)
Optic neuropathy
Dose to disc*   0.062 (0.031) 4.12 0.042 1.06 (1.00 - 1.13)
Distance to disc§  -0.079 (0.063) 1.61 0.20 0.92 (0.82 - 1.04)
SE = Standard error, CI = Confidence interval, IOP = Intraocular pressure
* continuous variable, 10 Gy
† continuous variable, years
‡ coding no=0, yes=1
§ continuous variable, mm
|| continuous variable, mmHg
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By univariate competing risks regression, IOP at diagnosis (P=0.10) and preoperative
exudative RD (P=0.094) were associated with time to glaucoma. Both increased in
significance when combined in a bivariate model (Table 5). In Cox regression models with
simulated dose distribution, secondary glaucoma was associated with dose to the opposite
retina (HR 1.90 for each 10 Gy increase, P=0.025), even when adjusted for tumor height and
IOP at diagnosis (P=0.024, Table 6).
Treatment of glaucoma after IBT is detailed in Study II. Briefly, glaucoma patients
were managed with medication and six (12% of all patients with glaucoma) underwent
transscleral contact krypton142 or red diode laser223 cyclophotocoagulation. Filtration surgery
was considered contraindicated. Eyes with light perception or worse vision were managed
with topical mydriatics and corticosteroids or with cyclophotocoagulation to provide
symptomatic relief in patients who wished to avoid secondary enucleation.142;223 Six (12%) of
the 51 eyes which developed glaucoma after IBT underwent secondary enucleation because of
pain unresponsive to therapy. All enucleated eyes had light perception or worse vision.
The risk for these complications appears to be influenced by multiple factors that are
not directly related to radiation, but which may contribute to ischemia of the ocular tissues.
Iris neovascularization can develop even in eyes with untreated large tumors.230;258 Large
tumor size is reported to predict NVG after IBT, but only tumor height was associated with
iris neovascularization and neither height nor LBD were associated with secondary glaucoma
in the present study. However, dose to the opposite retina which was associated with
glaucoma reflects both the total irradiated volume and the height of the tumor. This
association can be due to the heavier radiation burden to the eye as a whole or to the larger
tumor mass later to undergo necrosis, or both.
Glaucoma and iris neovascularization are reported to be more frequent complications
of brachytherapy if the anterior part of the tumor involves the iris,118 but such tumors were
ineligible. That the radiation dose to the chamber angle was not associated with either iris
neovascularization or glaucoma seems to indicate that the association between anterior
location of the tumor and these outcomes is not explained by direct radiation damage to the
anterior segment alone.
The results support an association between chronic RD, iris neovascularization,98 and
glaucoma. In addition, development of secondary glaucoma in this data set was associated




Iris neovascularization and subsequent glaucoma are a leading cause of secondary
enucleation of eyes where the tumor has been adequately controlled by
radiotherapy.78;108;200;256 It is also likely that they account for much of the vision loss in eyes
where radiation optic neuropathy and maculopathy have been avoided. Means to prevent
neovascular glaucoma after IBT, for example by reducing ocular ischemia and by promoting
resorption of RD23;98 should be investigated further. Laser-induced hyperthermia of the tumor
at the time of IBT45 and, in selected cases, resection of the leaking irradiated tumor (Bertil
Damato, unpublished observation) might prove useful in preventing chronic RD.
6.1.8.4. Maculopathy
The 5-year cumulative incidence of maculopathy was 52% (95% CI, 35%-65%; Fig10D).
Univariate competing risks regression, limited to the 80 eyes in which the distance of the
posterior tumor margin from the foveola was 2 mm or more, identified distance to foveola
(P=0.015) and gender (P=0.032) as factors associated with time to maculopathy. Both
retained significance when combined in a bivariate model and in bivariate models which
included age or diabetes as a confounding factor (Table 5).
There were 40 men and 40 women in the analysis of which 18 and seven,
respectively, developed maculopathy. The present study provides no explanation for this
association, which could have occurred by chance. On the other hand, environmental factors
such as cigarette smoking and underlying conditions such as systemic hypertension in which
there is a possible difference between the genders, were not analyzed.
Maculopathy developed in one patient when the dose to the macula was less than 40
Gy or the T:M ratio was more than 2.0, and to five patients when the dose was less than 50
Gy (Fig.4D,E in III). A statistical association between time to maculopathy and dose to
(P=0.47), or dose rate at (P=0.34), the center of the macula was not evident in Cox regression
models. Distance of the posterior tumor margin to the center of the fovea was significantly
associated with development of maculopathy, even when adjusted for dose to the macula (HR
0.84 for each 1 mm increase, P=0.015; Table 6).
Lack of a significant association between maculopathy and dose to the center of the
macula was contrary to some reports.37;116 Radiation maculopathy results from damage to
vessels which course around the macula to feed the foveal area. These vessels may receive
much larger doses than the fovea itself.116 After proton beam therapy, the risk for
maculopathy was reported to level off after a radiation exposure of 40 Gy to the fovea.116 The
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vast majority, or 84 of our patients, received at least this dose, weakening the possibility of
confirming an association between dose and maculopathy, should the same nonlinear
relationship apply to IBT. Moreover, some large melanomas can damage the macula
irrespective of radiation both directly and through exudative RD. Furthermore, the fact that
dose to the macula was strongly associated with loss of vision after IBT suggests that there
may be potential bias in assessing macular damage: many eyes were censored from analysis
after visibility to the fundus was lost and many of these had large macular doses.
Even though the risk for radiation maculopathy may not be as directly dose-related as
optic neuropathy, limiting macular dose by treatment planning and plaque design is justified.
A suggested aim could be keep the macular dose as much under 40 Gy as possible without
compromising local control. If maculopathy develops, intravitreal triamcinolone248 with or
without retinal photocoagulation141;157 may improve visual outcome at least in the short term.
It would be useful to know whether macular doses under 40 Gy correlate with the severity of
macular damage and its responsiveness to these treatments.
6.1.8.5. Optic Neuropathy
Cumulative incidence of optic neuropathy was 46% (95% CI, 30%-61%; Fig.10E) at 5 years.
Optic neuropathy developed in two patients when the dose to the optic disc was less than 50
Gy or the T:D ratio was more than 1.5 (Fig.4F,G in III). Patients with a T:D ratio less than 1
were 4 times as likely to develop optic neuropathy as those with a higher ratio (HR 4.37,
P=0.004).
Univariate competing risks regression identified two interrelated clinical factors,
distance to optic disc (P=0.015) and ciliary body involvement (P=0.0024), to be associated
with optic neuropathy. Distance to disc, chosen for bivariate models, remained significant
when adjusting for diabetes (HR 1.84, Table 5) or tumor height (data not shown).
Both tumor height and distance between the tumor and optic disc can act as surrogate
variables for dose to the optic disc. Indeed, in a bivariate Cox regression model which
included simulated dose to the optic disc, distance to disc lost significance (Table 6). Both
dose (HR 1.08 for each 10 Gy increase, P=0.001) and dose rate (HR 1.06 for each 10 cGy/h
increase, P=0.002) at the optic disc were strongly associated with this complication at the
univariate level.
The data suggest that the tolerance of the optic nerve for IBT was between 40 Gy and
60 Gy, in agreement with reports concerning optic neuropathy after other types of irradiation,
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which have suggested a threshold of 30 to 50 Gy.36;116;147;176 The sensitivity of the optic nerve
to high dose rates has also been documented by others.36;119
Because optic neuropathy often causes severe and irreversible vision loss and no
effective treatment is currently available, reducing dose to the optic disc should be a high
priority in treatment planning. This is routinely done in charged particle therapy planning but
should be included in the IBT protocol by using conformal seed placement and collimating
plaque design when necessary. Tumors touching the optic disk are a particular problem,
because even the most effective collimation is unlikely to lower the dose to tolerable levels
while maintaining adequate tumor dose to prevent recurrence.
6.1.8.6. Persistent Exudative Retinal Detachment
Exudative RD was present in 58 (61%) eyes at diagnosis and an additional 23 eyes had
subretinal fluid over and around the tumor. The RD resolved within 6 months in 42 (72%) of
the 58 eyes, and 19 eyes had or developed a RD which persisted for more than six months.
The 5-year incidence of persistent or progressive RD was 25% (95% CI, 15%-36%). The
proportion of patients with RD decreased from 31% (95% CI, 20-44) at 1 year to 13% after 5
years from IBT (Fig.2D in II).
Tumor height was associated with time to persistent RD in a univariate CRR model
(P=0.046). In bivariate models, it retained significance (HR 1.31 for each mm increase,
P=0.035) when adjusted for ciliary body involvement (HR 0.71, Table 5) and LBD (data not
shown), two factors associated with risk of RD in eyes with uveal melanoma.159 Substituting
tumor height with dose to the opposite retina in a bivariate Cox proportional hazards
regression model with ciliary body involvement did not improve the fit of the model.
Large LBD is associated with an increased, and ciliary body involvement with a
decreased, risk of RD in eyes with unselected, untreated uveal melanoma.159 These two
associations were present but not statistically significant in the present data set, possibly
because a substantial part of a large melanoma that involves the ciliary body extends to the
choroid and can leak under the retina.
It should be remembered that persistent or recurrent retinal detachment after
radiotherapy of a uveal melanoma can be a sign of disease activity.35;105;127;257 Even in cases
where local control has been achieved, persistent RD threatens vision and can predispose to
neovascular glaucoma.78;98;143 Unfortunately, the present study does not suggest any new
means to limit this complication. A study of medium-sized tumors suggested more rapid
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resolution of RD after pre-irradiation laser-induced hyperthermia.45 Managing all large
choroidal melanomas with laser or TTT before IBT may be impractical, however, especially
when many present with extensive RD at diagnosis. Removing the leaking tumor mass by
transvitreal endoresection in selected cases looks promising but the safety of this procedure is
yet to be established.29
6.1.8.7. Vitreous hemorrhage
Vitreous hemorrhage was present in 13 (14%) eyes at diagnosis. The cumulative incidence of
vitreous hemorrhage at 5 years after IBT was 36% (95% CI, 23-48%; Fig.10F). The
prevalence of vitreous hemorrhage after IBT fluctuated between 20% and 50% long term
(Fig.2C in II).
Vitreous hemorrhage present at diagnosis was associated with time to postoperative
vitreous hemorrhage in univariate competing risks regression (P=0.051) and in a bivariate
regression model that included tumor LBD (Table 5), but it lost significance when adjusted
for the presence of a break in Bruch’s membrane (data not shown). Postoperative vitreous
hemorrhage was not associated with any dose or dose rate analyzed.
In general, uveal melanomas which give rise to vitreous hemorrhage invade the
retina.146 It was impossible to reliably assess which patients had such a tumor because the
presence of this feature had not been assessed prospectively. It is unlikely that vitreous
hemorrhage after IBT can be influenced by treatment planning. Severe bleeding which
compromises visibility to the fundus and hinders vision can be cleared with post-treatment
vitrectomy.
6.1.9. Extrapolated Response Dose
Optic neuropathy and blindness, which were strongly associated with dose to the optic disc
and dose to the macula, respectively, were also associated with corresponding ERD, but the
association was weaker. In all other analyses, substituting dose with ERD resulted in loss of a
significant association with the outcome of interest, if present.
High dose rates are thought to be more damaging to late-reacting normal tissues than
to tumor cells. This effect increases with increasing irradiated volume,126 which was large in
this study. ERD was designed to take tissue susceptibility and dose rate effect into account.62
The lack of association between dose rate and ocular complications other than optic
neuropathy, and the fact that ERD was not superior to BPS dose in regression analysis, was
unexpected. However, the dose rate effect is reported to be less pronounced at rates of 60
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cGy/h or less,125 and more than half of the eyes in the present data set received an apical dose
rate lower than this. In support of this possibility, a study of smaller melanomas, which
reported a comparable mean macular dose (98 Gy vs. 101 Gy in the present study) but much
higher mean macular dose rate (139 cGy/h vs. 82 cGy/h), found the dose rate at the macula to
be more strongly associated with vision loss than dose to the macula and optic disc.148 At least
with the relatively low dose rates of the present study, ERD does not provide any additional
prognostic information compared to delivered dose alone. It would be interesting to see if
ERD would be of more value in assessing high-dose-rate treatment such as Strontium-90
brachytherapy.
6.1.10. Simulated Treatment with Collimating Plaques
Simulated treatments with collimating plaques and standard prescription doses graded
according to tumor height were modeled for 77 patients (58 managed with CCC and 19 with
CCB plaques). These models suggested a median decrease of 36 Gy (range, 19 Gy increase to
198 Gy decrease) in dose to the center of the macula and a median decrease of 30 Gy (range,
9 Gy increase to 160 Gy decrease) in dose to the optic disc, when compared to the BPS doses
of the actual treatments (Fig.11A). The median T:D and T:M ratios, based on these 77
patients, improved from 0.94 (range, 0.39-3.15) to 1.61 (range, 0.35-5.27) and from 0.99
(range, 0.27-2.59) to 1.81 (range, 0.36-4.04), respectively (Fig.11B).
Of 69 patients whose BPS dose to the macula had exceeded 50 Gy, 45 (65%)
avoided this level of radiation in the simulation with collimating plaques, and 23 (38%) of 60
patients avoided a 50 Gy dose to the optic disc (Fig.11B). This analysis confirmed that small
changes in plaque design may notably reduce radiation dose to the optic nerve, macula, and
other tissues adjacent to the tumor, increasing the therapeutic ratio without compromising
tumor dose. As a downside, such collimating plaques will require absolute safety margins.
Despite collimation, doses still exceeded the suggested tolerance limits in many patients.
The reduction in doses to the macula and optic disc achieved with collimating
plaques was, in some patients, partly due to the standard prescription dose graded by tumor
height, so that very thick tumors received 60 to 70 Gy instead of 80 to 100 Gy in the
simulation, as has been the practice in the study center more recently. The improvement in
T:M and T:D ratios, however, reflects the benefit from plaque redesign only.
Favorable theoretical dose distributions have been reported with plaques in which
each source is individually collimated.12 Ensuring an adequate dose to the entire tumor base
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and underlying sclera using individually collimated seeds would require the use of an
increased number of seeds of correspondingly lower intensity. Although a more radical
redesign would have further decreased the dose to tissues immediately adjacent to the plaque
edge, this zone less frequently extends to the macula and optic disc and it acts as a safety
border against marginal tumor recurrence. Furthermore, as one of the goals of this study was
to serve as a pilot for a prospective study of the collimating plaque design, it was reasonable
to conform as much as possible to the existing brachytherapy plaques and protocol.
By using a treatment planning software capable of detailed three-dimensional
modeling of the dose volume and the tumor eye and applicators with collimated seeds, it
seems possible to achieve more control over the irradiated volume in brachytherapy.
6.1.11. Strengths and Limitations
A clear strength of the present study is that it was carried out with a population-based data set
of consecutive patients managed in a national referral center that manages more than 90% of
uveal melanomas in the Finnish population. It is safe to say that the present series is currently
the largest reported population-based data set of patients with COMS Large melanomas
managed with an eye-conserving treatment. Another advantage is the availability of
prospectively collected and detailed patient records from both the study center and regional
hospitals which left just a few patients lost to follow-up and very few gaps in the data.







Dose to optic disc
Dose to macula
































Tumor : Disc (T:D)




















Figure 11. Plot of (A) dose delivered to the optic disc and macula using the original non-collimating plaques
(x-axis) vs. the prototype collimating plaques (y-axis) in the simulated treatment of 77 patients with a large
uveal melanoma. Solid line indicates no difference in dose. Dotted lines indicate proposed 50 Gy thresholds
of increased risk for complications. (B) Similar plot using Tumor:Disc and Tumor:Macula dose ratios (also
known as therapeutic ratios). Solid line indicates no difference in therapeutic ratio and dots falling above
this indicate patients in which the collimation improved the threapeutic ratio.
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Furthermore, the present study was able to reliably assess the causes of death in the majority
of deceased patients using histopathology samples instead of relying on death certificates in
which the possibility of late-metastasing malignancy such as uveal melanoma is sometimes
overlooked.164
A marked limitation of the present study is that it failed to prospectively address the
quality-of-life aspects after treatment, and such an analysis was no longer feasible without
introducing bias because many patients had died. Although most follow-up data have been
prospectively collected, some events of interest, such as persistence of RD, had to be re-
assessed by reviewing the patient records. A small proportion of patients had missing data,
and not all complications could be reliably assessed after visibility to the fundus was
compromised. The latter problem was taken into account by censoring patients from analysis
at that point.
A BPS simulation depends on the accuracy of clinical examination and, in
retrospective studies, on the quality of patient records. The position of the plaque in the model
cannot be completely controlled retrospectively, and the results should thus be interpreted
with caution until confirmed by prospective studies. Using extraocular muscles and limbus as
landmarks, retrospective positioning of the plaque with little ambiguity was found to be
possible in the majority of cases, with sufficient accuracy to suggest unobserved tilting of
some posteriorly placed plaques from the scleral surface along the optic nerve. Sensitivity
analysis suggested that the retrospective BPS doses to the tumor apex reported in the present
study should be essentially unaffected by error in placement of the seeds and the plaque in the
model, and that the simulated mean doses to the lens, macula and optic disc are unlikely to
deviate more than 5 Gy from the actual mean doses. The BPS off-axis doses are also subject
to up to 11% deviation due to mathematical approximations used by the software; in general
this error is reported to be 5% or less.162
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6.2. Transscleral Local Resection vs. Iodine Brachytherapy for Uveal
Melanomas that are Large Because of Tumor Height (IV)
6.2.1. Baseline Population Characteristics
The median age of patients was 46 years (range, 21-73) in the TSR arm and 66 (range, 35-85)
in the IBT arm. TSR was rarely given to patients older than 60 years, whereas 67% of IBT
patients were in this age group. Because of differences in health care systems, total follow-up
times were notably shorter in the TSR arm (median, 2.3 vs. 5.3 years; P=0.0002 Kruskal-
Wallis test). The center-related difference in follow-up times is unlikely to be a major source
of bias, because visual loss and the majority of complications analyzed occur within the first
three years after either treatment (II).27;158 Cumulative incidence analysis and competing risks
regression also take the varying lengths of follow-up appropriately into account.
6.2.2. Baseline Tumor Characteristics
The tumors tended to be thicker in the TSR arm (median height, 11.0 mm; range, 8.0-14) as
compared to the IBT arm (median, 10.6 mm; range, 8.2-13.3; P=0.086). There was no
difference in the distribution of LBD (P=0.20), the median of which was 12.9 mm (range 9.8-
16) in the TSR arm and 14.0 mm (range, 7.3-16) in the IBT arm (Fig.4B).
The anterior tumor margin involved the ciliary body in 24% of TSR patients and in
39% of those managed with IBT (P=0.24, Fisher’s exact test, two-sided). The posterior tumor
margin extended to within 2 mm of the optic disc in no eye managed with TSR as compared
to 39% of the eyes managed with IBT (P=0.017) and 24% vs. 20% of tumors were located
within 2 mm of the fovea (P=0.79), respectively (Fig.4D).
Differences in tumor size and patient age at baseline were adjusted for in the
regression models. In most models, including the baseline confounders strengthened the
association between treatment type and the outcome of interest.
6.2.3. Preservation of Visual Acuity
At baseline 11 patients (33%) in the TSR arm and 18 patients (33%) in the IBT arm had VA
better than 20/70. The 2-year cumulative incidence of losing 20/70 vision was 90% (95% CI,
47-99) in the TSR arm and 89% (95% CI, 62-97) in the IBT arm. (Table 7). All IBT patients
lost this level of vision in the tumor eye within 30 months but one regained it after cataract
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surgery. One patient in the TSR arm retained this level of VA (Fig.3A in IV) for at least 4
years.
Baseline VA of the tumor eye was better than 20/400 in 25 patients (75%) in the
TSR arm and in 42 patients (78%) in the IBT arm. After TSR, the cumulative incidence of
loss of VA 20/400 was 53% (95% CI, 31-71) at 1 and 60% (95% CI, 35-77) at 2 and 3 years
(Fig.3B in IV). After IBT, the corresponding incidences were 60% (95% CI, 44-73), 75%
(95% CI, 59-86) and 91% (95% CI, 76-97).
The mean VA after TSR was 20/320 to 20/640 throughout the first 5 years and
approximately one line better than the mean VA after IBT, which varied between 20/640 and
20/1250 (Fig.3C in IV).
The cumulative frequency of VA levels in the treatment arms was comparable at
baseline (P=0.68) but at 1, 2, and 3 year time points showed a statistically significant
difference between the arms. The proportion of patients with low VA increased with time in
both groups, but the effect was smaller in the TSR arm (Fig.12).
Figure 12. Cumulative frequency distribution of visual acuity at A, baseline; B, 1 year; C, 2 years; and D, 3
years after treatment of 33 patients managed with transscleral local resection (TSR) and 54 patients
managed with iodine brachytherapy (IBT), who had a uveal melanoma large by the COMS criteria only
because of its height. Kruskal-Wallis test.
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A multivariate logistic regression model was used to adjust for baseline VA, age, and
H:D ratio. Treatment with TSR was not consistently associated with avoiding loss of 20/70
vision. Treatment with TSR was independently predictive of avoiding loss of VA 20/400 at 1,
2, and 3 years, with the largest difference present at 2 years (P=0.005, Table in IV).
Better preservation of vision up to three years from the time of treatment was evident
in all three different types of analysis. Cumulative incidence of blindness, which evaluates the
timing of vision loss but lacks the ability to account for recovery of lost vision, suggests that
few new cases of blindness occur one year after TSR whereas the incidence after IBT steadily
increases. TSR was also associated with preservation of reading vision at two years but this
finding was not statistically significant at other assessed time points, possibly because of a
smaller difference and fewer patients at risk.
6.2.4. Local Tumor Recurrence
Local tumor recurrence developed in nine patients managed with TSR and in three managed
with IBT. The 5-year cumulative incidences of local recurrence were 41% (95% CI, 17-63)
and 7% (95% CI, 2-17), respectively (Fig.5A in IV). The 5-year recurrence rate was 37%
(95% CI, 7-66) in the TSR subgroup that received adjuvant irradiation treatment and 46%
(95% CI, 13-74) in the subgroup that did not. When comparing only those TSR patients who
received adjuvant radiotherapy with IBT, treatment with TSR was still statistically the most
significant risk factor for recurrence (P=0.023; CRR).
Of the nine patients with recurrence after TSR, six were managed with secondary
irradiation (three with RuBT and four with PBT), one with transpupillary thermotherapy, and
two underwent enucleation. Three of the patients managed with secondary radiotherapy
experienced a second relapse, and underwent enucleation. Two of the three patients with local
tumor recurrence after IBT were managed with secondary IBT and one underwent secondary
enucleation.
More frequent local recurrence has not been linked to higher mortality after TSR as
compared to IBT.158 Because recurrence after TSR usually results from tumor margins that
were not clear, it may not reflect increased malignancy of the tumor.53 The 5-year recurrence
rate was not higher than in eyes with smaller tumors,27;71;158 and the results are improving
with refinements of surgical technique.67;71 A greater risk of local recurrence nevertheless
remains a drawback of TSR and must be weighed against the prospect of avoiding blindness
in the tumor eye.
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6.2.5. Iris Neovascularization and Glaucoma
Iris neovascularization and glaucoma developed only in patients who underwent IBT. The 5-
year cumulative incidence of neovascularization was 64% (95% CI, 47-77) and that of
glaucoma 62% (95% CI, 45-75; Fig.5C in IV).
6.2.6. Optic Neuropathy
The 5-year cumulative incidences of optic neuropathy were 7% (95% CI, 1-19) and 58%
(95% CI, 36-75) after TSR and IBT, respectively (Fig.5E in IV). One of the three TSR
patients who developed optic neuropathy received RuBT as adjuvant therapy, but the
neuropathy resulted from ocular hypotony; one developed a swollen disc soon after surgery,
and the third presented with optic atrophy 7 years after TSR.
Adjusting for distance from posterior tumor margin to the optic disc identified IBT
(HR 3.74, P=0.042) as an independent predictor of neuropathy. Optic neuropathy is associated
with a radiation dose over 50 Gy to the optic nerve,116 which was exceeded in 43 (80%) eyes
in the IBT arm (III).
The incidences of neovascular glaucoma and optic neuropathy, two major
complications of IBT, were low after TSR and not different from previous series of mainly
smaller, unselected tumors.27;158 Avoiding these complications is likely to be the main
explanation for better preservation of vision after TSR in the present study.
6.2.7. Persistent Retinal Detachment
RD of more than one quadrant was present at baseline in 25 (76%) and 29 (54%) of the eyes
in the TSR and IBT arms, respectively (Fig.5F in IV). New RD after TSR was
rhegmatogeneous in type and the 5-year cumulative incidence was 42% (95% CI, 25-59). Of
the 14 patients with RD after TSR, nine underwent pars plana vitrectomy, one was managed
with a scleral buckling procedure alone, and three patients, all with total RD and no visibility
to the fundus, underwent enucleation. After IBT exudative RD persisted or reappeared in 11
patients with a 5-year cumulative incidence of 27% (95% CI, 14-42). The prevalence of RD
decreased rapidly and remained under 20% after TSR. The prevalence of RD in the IBT arm




The 5-year cumulative incidences of cataract, maculopathy and vitreous hemorrhage in both
treatment arms are shown in Table 7. All three were common after both treatments with
competing risks regression showing higher risk for cataract and maculopathy after TSR.
In the TSR arm retinal folds and preretinal fibrosis were found in seven eyes, cystoid
macular edema in three eyes, and involvement of the macula by the surgical coloboma in four
eyes. Direct scarring and atrophy of the macula was seen in four eyes and radiation
retinopathy in eight eyes after IBT. All cases of vitreous bleeding in patients managed with
TSR occurred within 6 months of surgery. Ten (48%) hemorrhages resolved spontaneously,
seven eyes underwent vitrectomy (six had other indications to surgery as well), and three eyes
with persistent vitreous hemorrhage and total RD underwent enucleation. In the IBT arm, one
of the 17 patients with vitreous hemorrhage underwent vitrectomy, six hemorrhages
spontaneously resolved and 10 persisted throughout follow-up.
Despite the high frequency of these complications after TSR in the present series,
preservation of VA was still better than after IBT.158 Although a detailed analysis of the exact
cause of the vision loss was not done, it stands to reason that many patients managed with
TSR avoided a profound and permanent loss of vision by avoiding NVG and optic
Table 7.  Summary of cumulative incidences of loss of 20/70 and 20/400 vision and of complications after
iodine brachytherapy (IBT) and transscleral local resection (TSR) of a uveal melanoma classified as large by
the Collaborative Ocular Melanoma Study criteria. Tumors eligible to Study IV were classified as large
because of tumor height alone.
Studies I-III Study IV
2-year cumulative incidence IBT IBT TSR
Loss of VA 20/70 85% (71-93%) 89% (62-97%) 90% (47-99%)
Loss of VA 20/400 69% (57-78%) 75% (59-86%) 60% (35-77%)
5-year cumulative incidence
Loss of VA 20/400 84% (73-91%) 95% (76-99%) 68% (40-85%)
Local tumor recurrence 6% (2-12%) 7% (2-17%) 41% (17-63%)
Cataract 79% (68-86%) 78% (62-88%) 91% (68-98%)
Iris neovascularization 62% (50-71%) 64% (47-77%) 0%
Glaucoma 60% (48-70%) 62% (45-75%) 0%
Maculopathy 52% (35-65%) 43% (22-62%) 63% (34-82%)
Optic neuropathy 46% (30-61%) 58% (36-75%) 7% (1-19%)
Retinal detachment 25% (15-36%) 27% (14-42%) 42% (25-59%)
Vitreous hemorrhage 36% (23-48%) 39% (23-55%) 67% (47-80%)
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neuropathy. Vision loss caused by cataract, rhegmatogenous RD or vitreous bleeding can be
remedied which leaves maculopathy to account for the relatively frequent loss of reading
vision observed.
6.2.9. Number Needed to Treat
Of patients with better than 20/400 vision at diagnosis, 13 in the TSR arm and 38 in the IBT
arm were under follow-up for at least 2 years after treatment. Five local tumor recurrences
were observed in the TSR arm and two in the IBT arm. In both groups five patients
maintained 20/400 vision for at least 2 years (range, 2.5 to 11). The number needed to treat
with TSR instead of IBT for one additional patient to gain this benefit was 4.0 (95% CI,
NNTB 1.9 - NNTB 570; Fig.7 in IV). The corresponding number to treat with TSR for one
more patient to be harmed by local recurrence was 3.0 (95% CI, NNTH 1.7 - NNTH 10.9).
If this estimate based on the present, relatively small data set can be verified in
independent, preferably prospective, studies, it may not be advisable to recommend TSR as a
first option for patients with uveal melanomas of this size under normal circumstances, i.e.
when the fellow eye is healthy and functional. In special situations, when it is imperative to
save as much vision as possible and the patient accepts the relatively high risk of local failure,
TSR seems the better choice. This conclusion must be re-evaluated when advances in TSR
protocol notably reduce the risk of local tumor recurrence.
6.2.10. Strengths and Limitations
TSR and IBT have been compared previously, both by our study centers and by others.27;158
One of the merits of the present study is that it focuses on the subgroup of tumors that
encounter the most problems after IBT and might thus, logically, fare better after TSR. The
present study also utilizes cumulative incidence analysis and competing risks regression to
factor out the confounding effect of early metastatic death. Finally, the preservation of vision
was analyzed using several different methods. By taking repeated loss and recovery of vision
and baseline risk factors into account and by estimating the proportion of patients with
various degrees of vision loss at different time points, these give a more complete picture of
how much vision is saved with TSR. NNT calculations should also prove helpful in
considering the benefits and risks associated with these two treatments for uveal melanomas
of this size.
Uveal melanomas that are classified as large because of their height are uncommon,
making it difficult to organize a prospective study with adequate sample size. The
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retrospective setting used in this study may introduce bias in treatment selection, follow-up
methods and baseline variables. A two-center design was used to limit selection bias in
choosing between the two treatments. This, however, introduced differences in follow-up and
in indications for secondary treatment. The different attitude toward secondary enucleation is
an obvious source of bias. Eyes managed with TSR in which fundus visibility or vision was
lost were enucleated in most cases. After IBT, the policy was to offer enucleation as a safety
measure if visibility was lost, but most patients refused this option and preferred to retain the
eye for cosmetic reasons (I). This not only makes the comparison of eye retention after the
two treatments biased but also risks overestimating any difference in complication rates in
favor of TSR. The latter problem was taken into account by censoring enucleated eyes from
analysis at the time of enucleation instead of analyzing enucleation as a competing risk. This
design produces an overall overestimation of the incidence of complications in both arms by
disregarding the fact that patients are no longer at risk of ocular complications after secondary
enucleation (II). The inability to detect posterior segment complications after fundus visibility
was taken into account by censoring patients from analyses after loss of fundus visibility.
Evolution of the treatment protocols in both study centers during the study period
resulted in earlier patients having been managed with a different protocol from the latest. In
particular, most later TSR patients received adjunctive RuBT while the earliest did not. It can
be argued that this causes internal variation within the TSR group which can affect the
outcome. The confounding effect of adjunctive RuBT, if any, should be most evident in local
failure after TSR and in the radiation-related complications in eyes where the tumor was
located close to the posterior pole. Local failure was less frequent in patients who received
adjunctive radiotherapy but still more common than after IBT. Substituting the whole TSR
group with only the 20 TSR patients who received adjuvant therapy in the CRR and logistic
regression models did not alter the outcome for local recurrence and preservation of vision,
the main outcomes of this study.
6.3. Conclusions
 In terms of survival, iodine brachytherapy in this series was a safe alternative to enucleation
in managing large uveal melanomas. Local tumor control was no worse than with medium-
sized tumors and chances to avoid secondary enucleation are good. Unfortunately, side-effects
from radiotherapy with the current brachytherapy protocol were frequent, and long-term
prognosis of saving usable vision was consequently guarded. Patients with very thick tumors
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close to the posterior pole have the highest risk of losing vision after IBT. Patients with
ciliochoroidal melanomas had the best chance of maintaining ambulatory vision and are least
likely to benefit from enucleation considering the higher risk of early metastatic death
associated with tumors involving the ciliary body.
While tumor height was the strongest clinical prognostic factor for vision loss after
IBT, dose to the macula and dose to the optic disc were also independently associated with
this outcome. Since the means to manage radiation damage to the optic nerve and macula are
limited, decreasing the dose absorbed by these critical structures should be a high priority in
brachytherapy planning. According to simulations, a clinically meaningful decrease might be
achieved by using brachytherapy plaques with appropriate seed collimation and a treatment
planning software capable of detailed three-dimensional modeling of the tumor eye and
plaque placement.
Even when the risk for optic neuropathy and radiation maculopathy can be decreased
by improved plaques and treatment planning, persistent exudative retinal detachment, iris
neovascularization and neovascular glaucoma can still cause considerable ocular morbidity
and permanent loss of vision. These complications should be anticipated in patients after IBT
of a large uveal melanoma and appropriate treatment given as needed. New effective methods
of treatment for these conditions as well as evidence-based data of the safety and
effectiveness of existing ones should be actively sought.
When discussing treatment of a large uveal melanoma, patients can be informed of
available treatment options for their condition and of the risk of vision loss, secondary
enucleation, local tumor recurrence and complications associated with each one. In a setting
with frequent competing risks, such as early metastatic death, cumulative incidence analysis
provides more realistic estimates for this purpose than the Kaplan-Meier method.
If a patient is unwilling to accept the risk of local recurrence and complications
associated with IBT of a large uveal melanoma, enucleation can be recommended as an
effective and proven treatment. On the other hand, if the clinical setting – such as a blind
fellow eye – demands, or the patient himself so prefers, TSR can be considered as an
alternative to IBT for tumors that are classified large because of their height in cases when it
is imperative to save as much vision as possible. In this case the patient must also be fit
enough to undergo hypotensive anesthesia and willing to accept the currently many-fold risk
of local tumor recurrence. For patients who do not fulfill these criteria but still prefer to retain
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their eye and avoid enucleation, IBT remains a safe option which provides good tumor control
and a reasonable cosmetic outcome.
6.4. Future Directions
The encouraging results of the simulated collimating plaque design need to be confirmed with
prospective, preferably randomized clinical studies. If found to be suitable for clinical use,
such plaques together with accurate and, ideally, conformal treatment planning should
increase the number of patients who maintain useful vision after IBT of a large uveal
melanoma. In order to avoid a reciprocal increase in local tumor recurrence, these new
techniques will demand high precision in plaque placement.
These techniques can potentially be used to improve the already better visual
prognosis of IBT for medium-sized melanomas. Further improvement in preserving the eye
and vision of patients with a medium to large uveal melanoma managed with any form of
radiotherapy can be expected once the underlying reasons for retinal detachment and
neovascular glaucoma are better understood and evidence-based means to prevent or manage
them are discovered. The high interest in neovascular processes in other fields of ophthalmic
and cancer research may help to provide the answers.
Cytogenetic means to identify aggressive uveal melanomas associated with high risk
of metastasis would be a major breakthrough not only for assessing survival prognosis and
investigating new means to battle metastasis, but also for choosing primary treatment for
tumors which are associated with high risk of ocular morbidity after radiotherapy. It then
might be even more justified to use local resection, either transscleral or transvitreal, to
manage the less aggressive melanomas with less fear of compromising survival.
It is likely that radiotherapy will remain the main eye-conserving option for many
large uveal melanomas. The void in controlled studies on managing main radiation-related
complications that limit visual results should be filled with prospective studies, such as
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